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II. ABSTRACT 
 
Hepatocellular carcinoma (HCC) is a major life threatening cancer world wide. Radical 
resection and liver transplantation are the two curative treatment options. However, when 
patients are diagnosed with HCC, the majority are in advanced stages thus limiting surgical 
options. Although bridging therapies such as transcatheter arterial chemoembolization 
(TACE), radio frequency ablation (RFA), and percutanenous ethanol injection (PEI) offer 
therapeutic options, new targeted strategies with less side effects, better prognosis, and easier 
tolerance are urgently needed.  
Targeted therapy of tumor cells is the future prespective for different types of cancer. Suicide 
gene therapy allows the transfer of genes responsible for converting nontoxic products to 
toxic drugs, finally inducing a cytotoxic bystander effect on tumor cells. Transfection of 
suicide genes into mesenchymal stem cells (MSCs) and using them as cellular vehicles is a 
novel and promising approach for gene therapy against cancer. MSCs are naturally recruited 
to the tumor sites, selectively proliferate there, and participate in the formation of tumor 
stroma and angiogenesis. Transfection of suicide genes into mesenchymal stem cells (MSCs) 
under the control of tissue-specific promoters has been proposed to allow a tissue-specific 
expression of genes. 
The goal of this study was to analyze the efficacy of engineered mesenchymal stem cell as 
therapy directed towards tumor stroma and angiogenesis of hepatocellular carcinoma. MSCs 
are in gerneral actively recruited to the stroma and angiogenic milieu of tumors where they 
enhance growth, angiogenesis, and metastasis. In this study murine MSCs were engineered to 
express reporter genes, or therapeutic genes, under the control of the CCL5 or Tie2 promoter, 
and adoptively transferred into mice with growing HCCs. The effect on tumor growth, 
proliferation, and angiogenesis was evaluated. MSCs isolated from bone marrow of C57BL/6 
p53-/- mice were stably transfected with red fluorescent protein (RFP) or herpes simplex virus 
– thymidine kinase (HSV-Tk) gene driven by the CCL5 or Tie2 promoter. MSCs were 
intravenously applied once per week over 3 weeks to nude mice bearing xenogeneic HCC 
tumors. RFP signals driven by the CCL5 or Tie2 promoter were detected accompanying 
stromal specific CCL5 and angiogenesis specific CD31 signals in MSC treated HCC samples. 
The MSC-HSV-Tk therapy groups treated intraperitoneal with the prodrug ganciclovir 5 to 7 
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days after stem cell application lead to 66% and 42% reduction of HCC tumor growth as well 
as tumor cell proliferation following either CCL5- or Tie2-promoter driven HSV-Tk 
expression (*p=0.027; p=0165). The highly selective expression of the therapeutic gene 
driven by different tumor environment-specific promoters in engineered MSCs represents a 
new targeted approach in cancer therapy and needs clinical validation. 
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III. INTRODUCTION 
3.1 Mesenchymal stem cells 
3.1.1 Background 
The cell populations referred as mesenchymal stem cells (MSCs) are usually isolated from the 
mononuclear fraction of bone marrow aspirates which are then depleted of CD45+ cells and 
subsequently isolated as a sub-population of cells that adhere to plastic tissue culture dishes. 
The term “mesenchymal” defines a progenitor cell with fusiform shape able to actively move 
- as compared to “epithelial” or “parenchymal”. A unique surface marker identifying MSCs 
has not yet been identified, necessitating the application of a panel of antigens for their 
characterization. These include the expression of CD105, CD73 and CD90 at higher than 95% 
in culture, and an absence of markers for CD14, CD34, CD19, HLA-DR and CD451. MSCs 
can proliferate for many passages in culture and have the ability to give rise to diverse cell 
types, including adipocytes, chondrocytes, osteoblasts2, pericytes3 and endothelial cells4.  
Researchers have recently made use of MSCs as delivery vehicles for gene therapy, in part 
due to their accessibility for genetic modification in vitro and their ability to be cultured and 
expanded in vitro. The cells are easily obtained from a simple bone marrow aspirate and can 
be readily expanded. Their extraordinary high proliferative capacity is thought to contribute to 
the in vivo maintenance of both tumor stroma and connective tissue in organs remote from the 
bone marrow. MSCs successfully engraft into tissues under conditions of increased cell 
turnover, for example, those triggered by tissue damage, or neoplastic growth. They have the 
ability to efficiently home to sites of tissue injury including tumor environments. The exact 
mechanism governing this recruitment is not well understood. MSCs are thought to show a 
strong tropism for tumors because the tumor environment can be considered as the equivalent 
of a chronic wound – e.g. “the wound that never heals”5-8. Furthermore, MSCs inhibit T-cell 
proliferation9, 10, induce T-cell apoptosis11, alter migratory property of T-cells12, and are 
resistant to natural killer cell-mediated cytolysis due to non-expression of MHC-I13. These 
evidences provide a plausible explanation for the immunopreviligy of MSCs. Each of these 
attributes contributes to the potential application of MSCs for cell-based delivery of 
therapeutic genes to solid tumors. 
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3.1.2 Genetically engineering MSCs in non-gastrointestinal cancer therapy 
Molecules that physiologically control cell proliferation are often produced locally in tissues, 
and are rapidly turned over when they enter the peripheral circulation (e.g. TGF- β, TNF-α, 
IL-2, INF- β). The application of these biologic agents for cancer therapy is limited by their 
short biologic half-life or excessive toxicity. For effective anti-proliferative therapy the 
biologic concentration of these or other therapeutic agents required to achieve a therapeutic 
effect can often be substantially higher than serum levels achievable after systemic 
administration at the maximally tolerated dose. Similar issues arise when one considers 
general questions of regional vs. systemic therapy using more focused biologic approaches, 
for example, the use of suicide gene therapy.  
An early application of MSCs as vehicles for cancer therapy was described by Studeny et al.14. 
The authors transfected hMSC with IFN-β which were then used to treat melanoma 
xenografts in mice. Injection of the transfected MSCs into the peripheral circulation lead to 
reduced tumor growth and prolonged survival of tumor-bearing mice. Subsequently, MSCs 
from different sources, including human bone marrow-derived MSCs (hBM-MSCs)15-18, 
human adipose tissue-derived MSCs (hAT-MSC)19, mouse bone marrow-derived MSCs 
(mMSC)20-23, and rat MSCs (rMSC)24-27, have been evaluated as vehicles for tumor therapy. 
The expression of diverse therapeutic genes including IFN-β14, 15, 17, TRAIL16, 19, IL-1220, 
CX3CL121, VEGFR-123, iNOS27, HSV-Tk22, 24-26 have been engineered into MSCs to allow a 
targeted release of the agents in models of melanoma14, 15, breast cancer16, 20, Lewis lung 
carcinoma21, glioma17, 22, 24, glioblastoma25, 26, cervical cancer19, and fibrosarcoma27. In each 
of these tumor models, treatment showed efficacy in the inhibition of local tumor growth, 
suppression of metastasis, or prolongation of animal survival (Table 3.1). 
Table 3.1. Transfected MSCs for non-gastrointestinal anti-cancer therapy 
MSC Transfecte
d products 
Tumor  Effect 
IFN- β Melanoma14, 15 
Breast cancer15 
Glioma17 
inhibit tumor growth, suppress 
pulmonary metastasis and prolong 
survival 
hBM-
MSC* 
TRAIL Breast cancer16 reduce tumor growth and metastasis 
hAT-MSC# TRAIL Cervical cancer19 inhibit tumor growth 
mMSC§ IL-12 Creast cancer20 significantly interfere with cancer 
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growth 
CX3CL1 
 
Lewis lung carcinoma21 inhibit growth of lung metastasis and 
prolong survival 
VEGFR-1 Lewis lung carcinoma23 decrease lung metastases and prolong 
lifespan  
 
HSV-Tk Leptomeningeal glioma22 reduce tumor size and prolong 
survival 
HSV-Tk Glioma24 
Glioblastoma25, 26 
tumor growth suppression, survival 
prolongation 
rMSC† 
iNOS Fibrosarcoma27 inhibit tumor growth 
*: hBM-MSCs, human bone marrow-derived mesenchymal stem cells; #: hAT-MSCs, human 
adipose tissue-derived mesenchymal stem cells; §: mMSCs, mouse bone marrow-derived 
mesenchymal stem cells; †: rat bone marrow-derived mesenchymal stem cells. 
 
3.1.3 Dual effects of MSCs on gastrointestinal cancers 
As shown in Table 3.1, in non-gastrointestinal cancers, MSCs have demonstrated comparable 
effects regarding tumor growth, metastasis, and animal survival. Control, or non therapeutic 
MSCs, are also recruited to the tumor site where they can function as stroma cells to support 
tumor development. However, in gastrointestinal cancers the biology appears more 
complicated as conflicting data exists regarding the biology of MSC in these tumor settings.  
Following subcutaneous co-injection of liver cancer cells and hMSCs transfected with the 
human telomerase reverse transcriptase (hTERT) gene, Qiao28 showed that the engineered 
hMSCs inhibited tumor growth through down-regulation of NF-κB or Wnt signalling 
pathways29. In contrast, our group has shown that systemically applied MSCs can strongly 
promote tumor growth in orthotopic pancreatic30, 31 or in hepatocellular carcinoma (HCC) 
models32.  
Similar experimental settings have shown apparently disparent results concerning the biologic 
effects of MSCs. Li et al.33 reported that hMSCs can enhance tumor growth in vivo in a s.c.  
HCC model, whereas MSCs were found to inhibit the invasion and metastasis of the same cell 
type in vitro. Interestingly, expression levels of TGFβ1 by the MSCs were decreased in both 
in vitro and in vivo experiments.  
MSCs appear to have a complex biology in other gastrointestinal cancers, including 
esophageal cancer, gastric cancer, and pancreatic carcinoma. Li et al.34 applied hMSCs 
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together with esophageal cancer cells subcutaneously in nude mice. The authors showed that 
hMSCs could promote tumor growth with increased tumor vessel formation in vivo. 
Interestingly, the MSCs were found to inhibit the proliferation and invasion of tumor cell in 
vitro. These effects were associated with a general down-regulation of canonical Wnt 
signaling28, 35. In a gastric cancer xenograft mouse model, You et al.36 injected hMSC 
transfected with the suicide gene cytosine deaminase (CD), which was followed by treatment 
with the prodrug 5-fluorouracil (5-FU).  This resulted in a prounounced inhibition of tumor 
growth. In a chronic Helicobacter felis induced gastric dysplasia mouse model, Wang37 
applied murine bone marrow-derived Lin-CD44hiSca1-cKit+CD34- MSCs via tail vein 
injection. Surprisingly, these MSCs were found to reduce tumor progression to low-grade 
gastric dysplasia, and correlated with reduced gastric IL-17F, IL-22, and ROR-γt gene 
expression. Kidd et al.38 showed that hMSCs with or without transfected IFN-β were both 
found to suppress tumor growth in the same orthotopic pancreatic cancer mouse model. This 
is in contrast to the results of our studies in an orthotopic pancreatic cancer model31, where 
control MSCs were found to strongly promote primary tumor growth and to increase 
metastases, whereas suicide gene (HSV-Tk) transfected MSCs substantially inhibited local 
pancreatic tumor growth and the incidence of metastases. 
 
3.1.4 Additional examples of genetically engineered MSCs in gastrointestinal cancer 
therapy  
Apparently contradictory reports of the biology of MSCs have been described in 
gastrointestinal cancers (summarized in Table 3.2). There are additional examples 
demonstrating MSCs in general promoting tumor growth and therapeutic gene engineered 
MSCs inhibiting tumor growth. Shinagawa39 intravenously injected hMSCs in an orthotopic 
colon cancer model which resulted in an enhancement of tumor growth and metastases. Using 
CD-transfected hAT-MSCs in a colon adenocarcinoma xenograft model, Kucerova et al.6 
could show tumor growth inhibition. Moreover, Chen40 and Hu23 transfected mMSC with IL-
12 and VEGF-1 and then successfully demonstrated prevention of colon cancer 
carcinogenesis in a mouse model, reduction of lung metastasis, and a prolongation of lifespan. 
Studeny published the first two reports describing hMSC-based gene therapy in tumor 
models14, 15.  Wolf41 argued that the selective homing of systemically injected human MSCs in 
this model might be too artificial to be relevant to the clinical situation. To address this, the 
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authors used a complete syngenic murine model as their experimental system where in 
addition to MSC engraftment into syngenic tumors they observed exogenously applied MSCs 
in additional tissue sites, including spleen, liver, and normal lung41. The authors suggested 
that human tumors may selectively attract human MSCs by secretion of human-specific 
chemoattractants.  
Our group has previously shown31 that GFP transfected mMSCs in an orthotopic murine 
pancreatic cancer model are effectively recruited to the tumor, but some signals were also 
found in spleen, lymph nodes, thymus, skin, and gut. More recent studies using imaging in 
xenogenic tumor models further support the effect of solid tumors in recruiting adoptively 
engineered MSC whether they are syngenic or xenogenic to the tumor cells32.  
The potential recruitment of adoptively transferred MSC to non-tumor tissue environments 
with associated side effects is a potential concern for the general adaption of this technology 
for the treatment of cancer.  
One approach is to specifically direct the expression of the transgene only in a tissue specific 
environment by using tissue specific promoters. Studeny15 made an early referral to the use of 
specific promoters. The authors transfected IFN-β into hMSCs using an adenoviral vector and 
as expected found that the inhibition of tumor cell growth by MSC-IFN-β cells was not 
permanent. Adenoviral vectors generally lack a sustained effect as adenoviral transgenes do 
not integrate into the genomes of transduced cells, and that the transgene copy number per cell 
declines as the virally engineering MSC cells proliferate in tumors. To this end a more 
sustained inhibition of tumor cell proliferation may be achievable through by using MSCs that 
are stably transfected with a plasmid that expresses IFN- β under the control of a conditional 
promoter. Loebinger16 made use of the inducible tetracycline-on system to activate MSCs 
transfected with TRAIL to treat different cancers. The Tet-on system allowed the TRAIL 
effector and the GFP reporter gene expression to be induced under the control of a 
tetracycline promoter following MSC engineering by a lentiviral vector. It allowed 
researchers to control the expression of the transgene through of the use of doxycycline. 
Our group has approached this question from a different perspective through the use of tissue 
specific promoters. The general concept makes use of the differentiative capacity of MSCs 
following their recruitment into tumor microenvironments to drive a more restrictive 
expression of a therapeutic transgene only in a specific tissue context (e.g. by activation of the 
transgene by tissue specific signals) thus potentially sparring non-tumor tissues from 
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“therapeutic” damage. 
In one example, we made use of the observations of Karnoub et al.42 who studied the role of 
MSCs in a xenograft model of breast cancer. The authors demonstrated that MSCs are 
actively recruited into tumor associated stroma. Once there, the MSCs actively secrete the 
chemokine CCL5.  We tested the use of the CCL5 promoter to drive the expression of the 
suicide transgene HSV-Tk (accompanied with GCV) by engineering MSCs in a syngeneic 
model of pancreatic cancer31. After verifying the induction of CCL5 by MSCs in the context 
of pancreatic cancer, the promoter was used to drive the expression of the tymidine kinase 
suicide gene (HSV-Tk). In the context of treatment with ganciclovir, strong inhibition of 
tumor growth was seen with this selective targeting of the tumor stroma approach. 
Importantly, treatment also significantly reduced metastases in this model. 
In a second set of experiments, expression of HSV-Tk was driven by the Tie2 
enhancer/promoter. The idea was to drive transgene expression in engineered MSCs only 
when a subgroup of tumor infiltrating MSCs differentiate to endothelial related cells in the 
context of tumor angiogenesis. The Tie2 targeting strategy also effectively inhibited growth of 
experimental pancreatic cancer30.  
In each of these settings, a refined targeting was achieved such that only when the engineered 
MSCs infiltrate the tumor and undergo activation/differentiation the promoters are driving the 
transgene activation. We refer to this as a “Trojan Horse” approach.  With this approach, even 
if engineered MSCs reach other organs, the effect of the transgenes will be limited as they are 
under the control of promoters that are not active in these other tissue settings (schematic 
view in Figure 3.1). 
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Table 3.2. Opposite effects of MSCs on gastrointestinal cancers 
Gastrointesti
nal cancer 
Author MSC effects Opposite effects MSC Transfecte
d reagent 
Author 
Gastric 
cancer 
Wang37 mMSC# reduced the progression to 
low-grade gastric dysplasia 
 inhibit tumor growth 
in vivo with 5-FC 
hMSC CD† You36 
Pancreatic 
cancer 
suppress tumor growth  suppress tumor 
growth in vivo 
hMSC IFN-β Kidd38 
   promote tumor 
growth in vivo 
mMSC GFP / RFP
 
Kidd, 
Cousin38, 43 
hMSC§, 
hAT-
MSC 
  inhibit tumor growth 
in vivo accompanied 
with GCV 
mMSC HSV-Tk 
Zischek, 
Conrad30, 31 
Hepatocellula
r carcinoma 
Qiao28 hMSC* inhibit tumor growth in vivo  promote tumor 
growth in vivo  
mMSC RFP Niess32 
    
 
inhibit tumor growth 
in vivo with GCV 
mMSC HSV-Tk  
 Li33 hMSC enhance tumor growth in vivo inhibit tumor cell invasiveness 
and metastasis in vitro 
   
Esophageal 
cancer 
Li34 hMSC promote tumor growth and 
increase tumor vessel in vivo 
inhibit proliferation and 
invasion of tumor cell in vitro 
   
#: Lin-CD44hiSca1-cKit+CD34- MSC; §: transfected without IFN-β; *: immortalized by hTERT; †: CD, cytosine deaminase. 
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Figure 3.1. Schematic view of target-expressed MSCs recruit to tumor.  The genes under 
the control of promoter/enhancer were transfected into MSCs, and these MSCs applied 
through peripheral circulation. The genes only expressed when the vehicle cell reached the 
tumor site, because of the promoter/enhancer started to induce tissue-specific transcription of 
target genes. If the MSCs reached other organs, the target genes cannot be expressed. 
 
3.2.Hepatocellular carcinoma 
3.2.1. Background  
Hepatocellular carcinoma (HCC) is a major health problem with over 660,000 new cancer 
cases per year, making it the sixth most common malignancy and the third most common 
cause of cancer-related death worldwide44, 45. In unresectable but yet curable patients, who 
constitute a major portion of patients, orthotopic liver transplantation remains the only 
curative option. The long transplant waiting list involved high dropout rates due to tumor 
progression and deaths46. Bridging therapies, such as TACE, RFA, and PEI have been applied 
but have only limited capability of prolonging survival in unresectable patients47. Thus, 
additional therapeutic strategies need to be evaluated to improve survival in HCC patients on 
the transplant waiting list. 
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3.2.2. Treatment of HCC 
3.2.2.1. Surgical resection 
Within selected patient populations, radical surgical resection is the primary treatment for 
HCC providing the highest chance of long-term survival. In recent years, the perioperative 
mortality has been reduced to less than 5% depending on the extent of resection and hepatic 
reserve48. Because of advances in surgical and radiologic techniques, advanced perioperative 
care, and more accurate indication determination, the outcome of HCC surgical resection is 
improving. However, when patients are diagnosed with HCC, they are generally in an 
advanced stage or with significant liver cirrhosis. In this regard, only 5% of diagnosed cases 
of HCC in the West, and 40% in Asia are within the established criteria for resection 
treatment. New treatment strategies are clearly need to address those patients that fall outside 
the surgical resection option44.  
 
3.2.2.2. Liver transplantation 
Liver transplantation has been used to tackle the problems of liver dysfunction and HCC 
simultaneously. It is considered to be the best treatment option for patients with one tumor 
and decompensated cirrhosis or multicentric small tumors49. The best candidates for 
transplantation generally have one HCC smaller than 5 cm or up to three nodules smaller than 
3 cm who, in tertiary referral centres, achieve 70% survival at 5 years, with a recurrence rate 
lower than 15%50-54. Although liver transplantation has completely changed the treatment for 
HCC, the shortage of donors has clearly reduced the potential benefits of this approach. 
During the long waiting time seen in some Western countries, there is a drop-out rate of 20-
50% of cases. Adjuvant treatments, such as chemotherapy, chemoembolisation and 
percutaneous ablation, can be used to slow some tumor progression. 
 
3.2.2.3. Trans-arterial embolisation therapy 
Trans-arterial embolisation is the most widely applied treatment for unresectable HCC. This 
therapy is based on the fact that most of the tumor’s blood supply is derived from the hepatic 
artery. Obstruction of hepatic artery causes extensive necrosis in the large vascularised HCC55, 
56. Trans-arterial embolization can induce ischemic necrosis in HCC, achieves partial response 
in 15-55% patients, and substantially delays tumor progression and vascular invasion57-60. In 
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order to improve the efficacy of trans-arterial embolisation, chemotherapeutic agents 
(chemoembolisation) have been administered together with the embolisation particles, and 
oils such as lipiodol that are selectively taken up by HCC. This treatment is limited to patients 
with preserved liver function and asymptomatic multinodular tumors without vascular 
invasion. Otherwise, it will cause higher incidence of treatment-induced liver failure, overturn 
the potential benefits. 
 
3.2.2.4. Non-surgical local ablative treatments 
Destruction of cancer cells by percutaneous treatment is achieved by chemical substances 
(alcohol, acetic acid) or by modifying the temperature of cancer cells (radiofrequency, 
microwave, laser, and cryoablation)61. Percutaneous ethanol injection (PEI), which kill the 
tumor by a combination of cellular dehydration, coagulative necrosis, and vascular thrombosis, 
achieves responses of 90-100% in HCC smaller than 2 cm, to 70% in those of 3 cm, and 50% 
in HCC of 5 cm in diameter62, 63. Compared with PEI, percutaneous injection of acetic acid 
has stronger necrotizing abilities, making it more useful in septated tumors64. The 
radiofrequency ablation (RFA) uses high-frequency alternating current to create heat around 
an inserted probe, resulting in temperatures greater than 60°C and immediate cell death. It can 
be applied percutaneously, laparoscopically, or during laparotomy, and it may provide better 
anti-tumor benefits than PEI in tumor larger than 3 cm. The 5-year survival estimates for RFA 
are 33-40%65, 66. In a review of 3670 patients treated by RFA, mortality was 0.5% and the 
complication rate 8.9%67. Cryoablation therapy, which uses a specialized cryoprobe to freeze 
and thaw tumor and surrounding liver tissue with resulting necrosis, has as disadvantage the 
so-called heat-sink effect, limiting the utility of freezing near major blood vessels and is  
associated to a relatively high complication rate from 8% to 41%64. 
 
3.2.2.5. Chemotherapy 
To prolong the survival of patients with unresectable HCC, systemic chemotherapy is also 
conducted. Albeit anthracyclines are considered the most effective agents and single-agent 
doxorubicin regimens have been widely used, the response rates of chemotherapy are low 
(<20%) with no survival advantage. Because of toxicity, especially in patients with underlying 
liver disease, systemic chemotherapy is neither recommended as first-line therapy nor as 
control treatment within clinical trials68-70. 
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3.2.3. Summary for this part 
The curative treatments for HCC are radical resection of tumor and liver transplantation. 
However, both have strict criteria for candidate selection. Meanwhile, liver transplantion is 
limited by availability of organ donors. Although the new bridging therapies, such as PEI, 
RFA, and TACE, facilitate to improve the prognosis of HCC patient recent years, they all 
have disadvantages, such as narrow range of patient´s selection, relative high complication 
rate, unspecific tumor killing, or influence of remnant liver function. To this end, new 
strategies, which are designed to be easily applicable and specifically targeting tumor tissue 
with low influence on normal liver, are urgently needed. 
 
3.3. Tumor microenvironment 
Malignent cells exist in a complex cellular and extracellular microenvironment referred to as 
the tumor stroma, which significantly influences the initiation and maintenance of the 
malignant phenotype71-73. Solid tumors are comprised of malignant cells and the supporting 
“normal” cells that comprise the stroma including fibroblasts, endothelium, pericytes, 
lymphatics, and generally, mononuclear infiltrates. These stromal cells are required for tumor 
survival and represent an important target for chemotherapeutic intervention74-76. The tumor 
stroma surrounding is of crucial importance for tumor growth, progression, recurrence, and 
metastases. 
Tumor stroma and tumor angiogenesis are the two important aspects of tumor progression. 
Karnoub and colleagues showed that in breast cancer MSCs are recruited to the tumor 
environment where they induce the expression of the chemokine CCL542. CCL5 (chemokine 
(C-C motif) ligand 5, also called RANTES, regulated upon activation of normal T cell) is a 
chemokine or chemotatic cytokine that has been shown to play diverse roles in 
immunoregulatory and inflammatory processes77. Further studies have shown that it is also a 
critical signal in tumor stroma and tumor neovascularization42, 78-81. CCL5 functions as a 
chemoattractant for blood monocytes, memory T helper cells and eosinophils. It causes the 
release of histamine from basophils and activates eosinophils. In addition, CCL5 is thought to 
contribute to tumor growth and metastasis by autocrine activation of tumor cells as well as 
through the recruitment of a number of stromal cell types to sites of primary tumor growth79-81.  
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Neoangiogenesis is a crucial step in the transition of a tumor from a small group of malignant 
cells to a macroscopic tumor lesion82, 83. Tumor growth is promoted when the proliferation of 
vascular endothelial cells is increased, and tumor growth is inhibited when the proliferation of 
vascular endothelial cells is targeted or suppressed. Therefore, angiogenic tumor vessels 
represent promising targets for the selective delivery of cancer therapeutics. Tie2 is an 
endothelial cell surface tyrosine kinase receptor, which binds Ang-1 or Ang-2, and has wide-
ranging effects on tumor malignancy that includes angiogenesis, inflammation, and vascular 
extravasation. Tie2 expression is increased in angiogenic “hot spots” during tumor growth and 
progression. 
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IV. MATERIALS UND METHODS 
4.1. Materials 
4.1.1. Cell lines 
4.1.1.1.Human hepatocellular carcinoma cell Huh7 
Huh-7 is a well differentiated hepatocyte derived cellular carcinoma cell line originally 
isolated from a liver tumor in a 57-year-old Japanese male in 1982. The line was established 
by Nakabayshi, H. and Sato, J.84. 
. 
4.1.1.2. Murine bone marrow-derived mesenchymal stem cell 
Mesenchymal stem cells were isolated from the bone marrow of C57BL/6 mice homozygous 
for the targeted deletion of p53 as described85. The p53 knockout phenotype lead to the partial 
immortalization of the cells and allowed expansion, culture and subcloning of the resultant 
MSC cells. The cell line has retained significant pluropotency86. The cells grew adherently 
and continuously in cell culture and retained significant pluripotency. After subcloning, single 
cell clones were selected and characterized. These CD34- MSCs express CD73 and CD105 
and lack CD14, CD45 and MHC class II86, 87. 
 
4.1.1.3.RFP or HSV-Tk engineered mesenchymal stem cell 
The cells were transfected with red fluorescent protein (RFP) or herpes simplex thymidine 
kinase (HSV-TK) under the control of Tie2 promoter and enhancer or under the control of the 
CCL5 promoter, respectively, to achieve tissue specific expression of the construct. Four 
MSC lines were produced: 1) C57BL/6 Tie2/RFP+, 2) C57BL/6 CCL5/RFP+, 3) C57BL/6 
Tie2/HSV-Tk+ and 4) C57BL/6 CCL5/HSV-Tk+. All vectors included a Bsr2 blasticidin 
resistance gene controlled by the CMV promoter used to select for transfected cells at a 
blasticidin concentration of 5 μg/mL. Schematic diagrams of these four vectors are shown in 
Figure 4.1. 
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Figure 4.1. Schematic diagrams of the vectors of Tie2/RFP, Tie2/HSV-Tk, CCL5/RFP, 
and CCL5/HSV-Tk, which are stably transfected into C57BL/6 p53-/- mesenchymal stem 
cell. 
 
4.1.2. Technical equipements 
Freezer -80°C  Heraeus, Hanau, Germany 
Freezer -20°C                                                            Siemens AG, Germany 
Fridge 4°C  Siemens AG, Germany 
Automatic pipettes                                                    Gilson, Middleton, WI, USA 
AxioCam MRc5 camera                                            Carl Zeiss GmbH, Germany 
Microscopes                                                              Carl Zeiss GmbH, Germany 
Centrifuges                                                                Eppendorf, Germany 
CO2 Incubators                                                         Heraeus, Rodenbach, Germany 
Digital Precision Scale                                              KERN & Sohn GmbH, Germany 
Microwave oven                                                        Siemens, Germany 
Hand tally counter                                                     Carl Roth GmbH, Karlsruhe, Germany 
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Liquid nitrogen tank                                                  MVE, New Prague, MN, USA 
Vortex                                                                        IKA Works, Wilmington, NC, USA 
Water bath                                                                 GFL, Burgwedel, Germany 
Thermo Scientific Heraeus Incubator                       Thermo Fisher Scientific Inc, Germany 
Herasafe EN12469 2000 Class II Safety Cabinet     Thermo Fisher Scientific Inc, Germany 
TECAN GENios Plus ELISA reader  TECAN, Salzburg, Austria 
Leica RM2255, Fully Motorized Rotary Microtome   
                                                                                   Leica Microsystems, Nussloch, Germany 
RNA/DNA Calculator                                               GeneQuant Pro,  
                                                                                   GE Healthcare Life Sciences, USA 
Applied Biosystems 7000 Real-Time PCR System  Applied Biosystems, USA 
Automatic Tissue Processors Model 2065/2             MDS Group GmbH, Buseck, Germany 
Philips Infrared Lamp                                                Philips Consumer Lifestyle, Drachten,  
                                   Netherlands 
 
4.1.3. Cell culture materials 
Sterile tissue culture plastic flasks                            NUNC, Roskilde, Denmark 
Centrifuge tubes 15 mL                                             TPP, Switzerland 
Falcon tubes 50 mL                                                   BD, NJ, USA 
Hemacytometer and cover-slip (Cell counting chambers)   
                                                                                   Bürker-Türk, Germany 
Cryotube (1.0 mL)                                                     NUNC, Roskilde, Denmark 
Eppendorf safe-lock tubes (1.5 mL, 2.0 mL)            Eppendorf AG, Hamburg, Germany 
6-well culture plates                                                  Nunc, Roskilde, Danmark              
     
4.1.4. Medium, buffer, solution for cell culture 
RPMI 1640 + Glutamax-1 500 mL  61870-044, Gibco Invitrogen, Germany 
Fetal Bovine Serum 500 mL    Biochrom AG, Berlin, Germany 
Penicillin/Streptomycin 100 mL (10.000 Units Penicillin/mL, 10 mg Streptomycin/ml)   
                                                                                  PAN Biotech GmbH, Germany 
Trypsin0.05%/EDTA0.02 % in PBS without Ca2+ and Mg2+ 100 mL 
 - 24 -
                                                                                  PAN Biotech GmbH, Germany 
PBS-buffer             Biochrom AG, Berlin, Germany 
DMSO (Dimethylsulphoxide)             Sigma-Aldrich, Steinheim, Germany 
Trypan Blue (0.4%)               Sigma-Aldrich, Steinheim, Germany 
 
4.1.4.1.Cell culture medium  
RPMI 1640+ Glutamax-1 Medium      plus           10% FCS 
                 100 IU/mL Penicillin 
                 100 µg/mL Streptomycin 
 
4.1.4.2.Cell storage medium 
90% FCS                   plus           10% DMSO      
 
4.1.5. Materials for immunohistochemistry 
Neo-Clear® (Xylene substitute)                                Merck, Darmstadt, Gemany 
Ethanol  70%, 80%, 96%, 100%              CLN GmbH, Niederhummel, Germany 
TRIZMA Base     Sigma-Aldrich, Steinheim, Germany 
TRIZMA Hydrochloride    Sigma-Aldrich, Steinheim, Germany 
Sodium chloride     Merck, Darmstadt, Gemany 
Hydrogen peroxide 30% (H2O2)              Merck, Darmstadt, Gemany 
Albumin from bovine serum (BSA)                          Sigma-Aldrich, Steinheim, Germany 
Target retrieval solution 10×                                     Dako, CA, USA 
Avidin/Biotin blocking kit                                        Vector Laboratories, CA, USA 
Normal rabbit serum                                                 Vector Laboratories, CA, USA 
Normal goat serum                                                    Vector Laboratories, CA, USA 
Mayer’s hemalum solution    Merck, Darmstadt, Gemany 
Kaiser’s glycerol gelatine    Merck, Darmstadt, Gemany  
Triton® X-100                                                           Sigma-Aldrich, Steinheim, Germany 
Vectastain® ABC kit                                                 Vector Laboratories, CA, USA 
Liquid DAB+ substrate chromogen system              Dako, CA, USA 
Monoclonal rabbit anti-Ki67 antibody                     Abcam, UK 
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Polyclonal rabbit anti-CD31 antibody                      Abcam, UK 
Polyclonal goat anti-mouse CCL5/RANTES antibody 
                                                                                   R&D systems, USA 
Polyclonal goat anti-human CCR5 antibody             Novus, USA 
Polyclonal rabbit anti-RFP antibody                         MBL, Japan 
CKR-1 (C-20) anti-CCR1 antibody                          Santa Cruz, USA 
 
4.1.5.1.Tris-buffer 
1 L H2O (dest.)  plus   0,9 g/L TRIZMA Base 
6,9 g/L TRIZMA Hydrochloride 
8,8 g/L Sodium chloride 
Adjust pH to 7.5 
 
4.1.5.2.Tris buffered saline (TBS) buffer, 10× 
1 M                                                                            Tris-HCl, pH7.4 
1.5 M                                                                         NaCl 
 
4.1.5.3.PBS wash buffer, 1× 
140 mM                                                                    NaCl 
2.7 mM                                                                     KCl 
10 mM                                                                      Na2HPO4 
1.8 mM                                                                     KH2PO4 
High purity dH2O, adjust pH to 7.4 
 
4.1.6. Materials for animal experiment 
4.1.6.1.Animals 
Bagg-albino/c(Balb/c) nu/nu male mice             Charles River, Sulzfeld, Germany 
(8-10 week old, 20-22g) 
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4.1.6.2.Surgery instruments 
Forceps                             Dosch GmbH, Heidelberg, Germany 
Disposable scalpels                                                   Feather Safety Razor Co., Japan 
Scissors, sharp / blunt      Dosch GmbH, Heidelberg, Germany 
Needle holder                  Dosch GmbH, Heidelberg, Germany 
 
4.1.6.3.Medicine 
Growth Factor Reduced (GFR) BD MatrigelTM Matrix10mL 
                                                                                  354230, BD Biosciences, USA 
Ketaminhydrochlorid (Ketavet®) 100mg/mL          Pfizer Pharmacia GmbH, Berlin Germany 
Xylazinhydrochlorid, Xylazin (Rompun®) 2% 25mL  
                                                                                   Bayer Healthcare, Leverkusen, Germany 
Ganciclovir (Cymeven®) 500mg              Roche, Grenzach-Wyhlen, Germany 
 
4.1.6.4.Other materials 
Normal saline                                                            Braun AG, Germany 
BODE Cutasept® F                Bode Chemie, Hamburg, Germany 
Syringe (1mL, 5 mL)                BD PlastipakTM, Madrid, Spain 
Hypodermic needle(30G)                                    B-Braun, Melsungen, Germany  
Injection needle (20G)                                              BD MicrolanceTM, Spain 
Thread with needle USP 4/0 Seralon®,                   Serag-Wiessner AG, Naila, Germany 
Rotilabo®-embedding cassettes                               Carl Roth GmbH, Karlsruhe, Germany 
4% Formalin                                      Pathology LMU, Germany 
Q-tips (cotton applicator)                                          NOBA, Wetter, Germany 
 
4.1.7. Materials for ELISA 
Mouse CCL5/RANTES DuoSet ELISA Development kit 
                                                                                    R&D Systems, Minneapolis, USA  
Wash buffer                                                                PBS wash buffer plus 0.05% Tween-20      
Reagent Diluent                                                          1% BSA in PBS 
Substrate Solution                                                       BD optEIA TMB Substrate Reagent Set 
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Stop Solution                                                              H2SO4       
Streptavidin-HRP                                                       BD Pharmingen, Germany 
 
4.1.8. Materials for qRT-PCR 
RNeasy Mini Kit (250)                                              QIAGEN, Hilden, Germany 
High-capacity cDNA reverse transcription kit          Applied Biosystems, USA  
Platinum Quantitative PCR SuerMix-UDG with ROX 
                                                                                   Invitrogen, USA 
TaqMan Gene Expression Assays: 
              CCL5, Hs00174575_m1 
              CCR5, Hs99999149_s1 
              TEK (Tie2), Hs00945146_m1                     Applied Biosystems, USA 
Eukaryotic 18S rRNA Endogenous Control (VIC/TAMRA Probe, Primer Limited) 
                                                                                    Applied Biosystems, USA 
β-Mercaptoethanol                                                     Sigma-Aldrich, Steinheim, Germany 
Liquid nitrogen                                                           Klinikum Grosshadern, LMU, Germany 
Dry ice                                                                        Klinikum Grosshadern, LMU, Germany 
Mortar and Pestle                                                       Carl Roth GmbH, Karlsruhe, Germany 
RNase-free filter tips                                                  Starlab GmbH, Ahrensburg, Germany 
 
4.1.9. Software 
Adobe Acrobat 7.0 Professional                                Adobe Systems Inc., USA 
Axio Vision 4.4                                                          Carl Zeiss GmbH, Germany 
Microsoft Office 2003 (Word, Excel, Powerpoint)  Microsoft Corporation, USA 
EndNote X3 (Windows Version X3)    Thomson Reuter 
IBM SPSS Statistics 19                                              SPSS STATISTICS Inc., USA 
Windows XP Professional                                          Microsoft Corporation, USA 
SoftMax® Pro                                                              Molecular Devices Corp., USA 
Image-Pro Plus 5.0                                                     Media Cybernetics, Inc., USA 
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4.2. Methods 
4.2.1. Cell culture conditions 
All kinds of cell lines used in this experiment were incubated at 37°C under 5% CO2.  The 
humidity of the incubator was 98%. Cells were keeping cultured in 75 cm2 or 175 cm2 flasks, 
and the medium was changed every 3 days.  
 
4.2.2. Passage of cells 
The cells grew until 80-90% confluent, and then were washed once by 1× PBS. Cells were 
passaged by brief trypsination with 0.025% trypsin (Trypsin/EDTA, PAN biotech GmbH, 
Aidenbach, Germany). 
 
4.2.3. Determination of cell number 
The dye Trypan Blue stains dead cells with membrane defects. Thus, living and dead cells can 
be distinguished by their ability to exclude the blue dye. 
100μL of the cell resuspension was aspirated into 1.5mL Eppendorf tube, then added an equal 
volume of 0.4% Trypan Blue and gently mixed. The hemacytometer was prepared by first 
cleaning the chamber surface with 70% ethanol, then covered with cover-slip (Figure 4.2 a). 
10μL of the stained cells was added into the space between the cover-slip and hemacytometer 
chamber. Using a hand tally counter, the number of viable (unstained) cells was counted in an 
area of 16 squares. As shown in Figure 4.2 b, the cell number was counted using the 
microscope, and was determined in four 16-corner-square regions (blue, Figure 4.2 b). The 
counting rule is schematically shown in Figure 4.2 c, which means that cells riding on the 
lines of the  lower and left quarter are included, whereas cells on the lines of the upper and 
right quater are excluded (red ones are included, and white ones are excluded, Figure 4.2 c). 
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Figure 4.2. Determine the cell number. a) Hemacytometer and cover-slip; b) A sketch of the 
gird seen on a hemacytometer, cells are counted in four sets of 16 squares at each corner of 
the grid (in blue); c) Schematic picture of cell-counting rule in one small square. 
 
The cell count was summed up from all 4 sets of 16 corner squares. This total number was 
divided by 4 to find the average number, and then multipled by 2 (to adjust for the 1:2 dilution 
factor with trypan blue). Finally, the concentration of cells per mL was obtained as 
multiplying by 1 × 104 (the formula listed below). 
Cell number / mL = (4 blue-region total cell number / 4) × 2 × 10000 
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4.2.4.  Storage and recultivation of the cells 
4.2.4.1.Storage of the cells 
The cell resuspension number was detemined by the method mentioned above. Normally, the 
cells were stored in 1 to 4 million per cryotube (1.0 mL). Then 1 to 4 million cells were 
centrifuged at 350g (rph) for 5 minutes, and the supernatant was aspirated. The remaining cell 
pellet was then suspended with 1mL Fetal Bovine Serum and 10% DMSO. The 
dymethylsulphoxide (DMSO) is a cryprotective agent which can minimize the cellular injury 
by freezing and thawing procedures, such as intracellular ice crystals and osmotic effects. The 
tubes are moved to a gradually temperature-decreasing tank and then kept in a -80°C freezer. 
After 72 hours, the tubes were moved to a liquid nitrogen tank for long-time storage. 
 
4.2.4.2.Recultivation of the cells 
The culture medium was first aspirated into the cell culture flask. The frozen tubes were taken 
out of the liquid nitrogen tank, and were immediately put into the 37°C water bath for 1-2 
minutes. After almost complete thawing of the cells, the tubes were taken out of the bath. The 
cells were then added into the cell culture flask. After one day of culturing in the incubator, 
the medium was changed to avoid toxic effect of the remaining DMSO.  
 
4.2.5. Orthotopic hepatocellular carcinoma mouse model 
4.2.5.1.Animals 
The 6- to 8-week old, 18-20g weight of Balb/c (Baggalbino/c) nu/nu mice were obtained from 
Charles River, Inc (Sulzfeld, Germany). All animal experiments were conducted according to 
German legislation for the protection of animals. 
 
4.2.5.2.Animal’s living conditions 
Animals were housed and maintained in laminar flow cabinets under specific pathogen-free 
conditions with free access to food and water.  
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4.2.5.3.Anesthesia  
The mice were anesthetized using 100mg/kg Ketaminhydrochlorid (Ketavet®) and 5mg/kg 
Xylazinhydrochlorid (Rompun®). The mixed anesthesia reagent was injected intraperitoneally. 
Normal saline, Ketavet and Rompun were mixed in a ratio of 1:1:1 (1 mL of each). The 
intraperitoneal injection volume for each mouse was 50 uL of this solution.  
 
4.2.5.4.Surgical techniques  
4.2.5.4.1. Intra-hepatic Huh7 cell injection 
The operation site was prepared in a sterile manner. A 1 cm incision in the midline of the 
upper abdomen was performed and the lateral lobe of liver was exposed. A 1 ml syringe and 
30G needle were used to inject 1 x 106 Huh7 human hepatocellular carcinoma cells in 40μl 
PBS mixed with 40μl Matrigel (BD Biosciences, USA) into the left lobe of the liver. To avoid 
spilling into the peritoneal cavity, a Q-tip was pressed lightly on the injection site for one 
minute after the needle was pulled out of the liver. After injection of the tumor cells, the 
peritoneum and skin were closed with interrupted sutures of USP 4/0 Seralon (Serag-Wiessner 
AG, Naila, Germany). The procedure is shown in Figure 4.3. 
 
Figure 4.3. Intra-hepatic Huh7 cells injection. a) The median incision of the mouse 
abdomen was conducted to expose the left lateral liver lobe; b) Q-tips were used to better 
expose the liver lobe; c) Injection of Huh7 cells into the liver lobe. 
 
4.2.5.4.2. Ear markers 
In order to distinguish the mice in the whole process of the experiment, the mice were marked 
using ear markers. The ears were marked with ear staples (Figure 4.4) right after the surgery 
and still during the anesthesia. 
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Figure 4.4. The mouse ear marker and the hole on the mouse ear 
 
The ear markers were conducted as shown in Table 4.1.: 
Table 4.1. Schematic pictures of mouse ear markers 
Mouse 
number 
Ear Marker 
Mouse 
number
Ear Marker 
Mouse 
number
Ear Marker 
1 
 
6 11 
2 
 
7 12 
3 
 
8 13 
4 
 
9 20 
5 
 
10 30 
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4.2.5.4.3. Injection of eMSCs 
The Philips Infrared Lamp (Philips Consumer Lifestyle B.V., Drachten, Netherlands) was 
used to warm up the tails of the mice for vein dilation, so that the eMSCs can be easily 
injected into the tiny tail veins. 
Tail vein injections were conducted without anesthesia to better observe pulmonary embolism 
which is the most critical problem in this procedure. In order to better observe the mice 
breathing during and after the peripheral injection, we kept the mice awake and adjust our 
procedure according to their respiration (e.g., slow down the injection rate, oxygen inhalation, 
etc.)  
For intravenous tail vein injection the animals were kept in cylindric chambers to limit their 
activity and completely expose their tail. The cells were then slowly injected as shown in 
Figure 4.5. 
 
Figure 4.5.  Nude mouse tail vein injection 
 
4.2.6. Injection of SPIO-transfected MSC in tumor-bearing mice 
4.2.6.1.Labeling of MSC by transient supermagnetic iron oxide (SPIO) transfection   
The SPIO-containing contrast agent Resovist (Bayer Schering Pharma AG, Berlin, Germany) 
was used for labelling of MSCs. Resovist is a clinically approved carboxydextran-coated 
SPIO with an average hydrodynamic diameter of 60 nm. Its iron oxide particles have an R1 
relaxivity of 4.6 mM−1s−1  and an R2 relaxivity of 143 mM−1 s−1  at 37°C and 3T88. 
The liposomal agent Lipofectamine (Invitrogen, Berlin, Germany) was applied for labelling. 
Contrast agents at a dose of 50 μg Fe were pre-mixed with 20 μL Lipofectamine in a total 
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volume of 100 μL DMEM and incubated for 30 min at 37°C. Then the volume was increased 
to 0.8 mL of contrast medium. The SPIO – Lipofectamine complexes were added to the cells. 
Afterwards the cells were incubated for 4h under standard cell culture conditions (37°C, 5% 
CO2). To eliminate residual contrast agent particles, cell samples were washed at least three 
times with DMEM after the incubation. Afterwards, cells were resuspended in 0.3 mL DMEM 
and filtered through a 30-μm Filcon filter (BD Immunocytometry Systems, Erembodegem, 
Belgium) to avoid cell agglutination. To determine the effectiveness of the labelling 
procedure, the intracellular SPIO-particles were stained with Prussian Blue. The presence of 
extracellular, membrane-associated SPIO–Lipofectamine complexes was microscopically 
excluded. The iron oxide-labelled cells were counted in a Neubauer counting chamber. For 
MR imaging, unlabelled and labelled cells (1×106) were centrifuged in Eppendorf tubes and 
resuspended in PBS. 
 
4.2.6.2. In vivo MR-Imaging of SPIO-labeled MSC 
Mice carrying hepatocellular carcinoma four weeks after tumor cell inoculation received 
intravenous injections of sterile normal saline, 1x106 unlabeled C57BL/6 MSCs, or 1x106 
supermagnetic iron oxide (SPIO) labeled C57BL/6 MSCs (MSCiron) (as shown in Figure 4.6). 
Thirty-six hours after the respective injections mice were sacrificed directly before evaluation 
with MR imaging. As control, mice without prior tumor cell inoculation also received normal 
saline or MSCiron injections and were scanned by MRI as well (n=2 animals in each group).  
 
Figure 4.6. SPIO-transfected MSCs injected into HCC-bearing mice 
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The transfected SPIOs cause disturbances of the magnetic field, leading to a signal decay, 
which can be detected with T2- and T2*-weighted MR-sequences. Increasing iron 
concentrations lead to a decreasing T2* relaxation time of the surrounding tissue. The rate of 
spin dephasing, R2*, is therefore an index of the iron concentration in tissue (R2* = 1/T2*). 
However one must note, that other factors, e.g. hemosiderin or bowel air may cause a similar 
drop in signal, i.e. increasing R2*89. Therefore, areas of increased R2* signals were correlated 
with areas of vital tumor in the T2-weighed MR imges as well as by Prussian Blue staining in 
histology to confirm the SPIO-labeled MSCs as the origin of the iron particles. 
Imaging was performed with a clinical 3T-Scanner (Magnetom Verio, Siemens Healtcare 
Sector, Erlangen, Germany) using a dedicated 8-channel-mouse-coil. The animals were 
placed in a head first - prone position. Coronal T2-weighted TSE sequences (repetition time 
(TR) 2930ms; echo time (TE) 89ms, matrix: 384x384, FoV: 79x70mm, slice thickness= 1mm, 
flip angle=150°) and coronal T2*- weighted-sequences (3D FLASH, Matrix=448×112, 
FoV=37×150mm, slice thickness=1mm, flip angle=15°) with increasing TEs were obtained 
(TR 50ms; TE6/8.5/10/15ms). 
Postprocessing was performed with an in-house built MatLab-Software (7.2.0.529 (R2009B)). 
A pixel-based fit to the signal decay over the increasing echo times was computed, resulting 
in color-coded R2*-maps. This work was performed in collaboration with Dr. Mike 
Notohamirodjo, Department of Clinical Radiology, University Hospitals Munich. 
 
4.2.7. Experimental setting 
All mice were randomized into the respective experimental groups (as shown in Table 4.2).  
Group A: no stem cells or GCV injections (n=10 mice) 
Group B: C57BL/6 Tie2/RFP+ MSCs injections (n=5 mice) 
Group C: C57BL/6 CCL5/RFP+ MSCs injections (n=5 mice) 
Group D: C57BL/6 Tie2/HSV-TK+ MSCs and GCV injections (n=10 mice) 
Group E: C57BL/6 CCL5/HSV-TK+ MSCs and GCV injections (n=10 mice).  
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Table 4.2. Group design of the reporter gene engineered MSCs and suicide gene 
engineered MSCs in HCC-bearing mice 
Groups Transfected vector 
GCV 
injection 
Control No MSCs No GCV 
Non-therapeutic MSC group   
P53-/-  
Tie2/RFP+ eMSC 
No GCV 
 
P53-/- CCL5/RFP+ 
eMSC 
 
No GCV 
Therapeutic MSC group   
P53-/-  
Tie2/HSV-Tk+ eMSC 
GCV 
 
P53-/- CCL5/HSV-Tk+ 
eMSC  
GCV 
 
All stem cell injections were dosed at 0.5×106 cells per week and administered via the tail 
vein. Ganciclovir (Cymeven©, Roche, Germany) injections of group D and group E at a dose 
of 1.5 mg/mouse were applied intraperitoneally on days 4 to 6 after the stem cell injections (as 
shown in Figure 4.7). All mice were killed after three cycles of treatment (five weeks after 
tumor cell inoculation) and the liver specimen including tumors as well as other organs were 
harvested and weighed. 
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Figure 4.7. Genetically engineered MSCs injected into HCC-bearing mice. a) Schematic 
picture of genetically engineering MSCs injected into HCC-bearing mice; b) Timeline of the 
suicide gene engineering MSC combined with GCV injection in HCC-bearing mice. 
 
4.2.8. Histology 
4.2.8.1. Haematoxylin Eosin (HE) staining 
All liver tumors were formaldehyde-fixed and embedded in paraffin wax. Then 2µm serial 
sections were generated. Tissues were deparaffinized in xylene, and rehydrated in a graded 
series of ethanol. After 8 minutes in Mayers Haematoxylin immersion, the sections were 
washed 8 minutes with warm running water. Then the sections were immersed several 
seconds in Millipore water and stained with 0.1% Eosin solution for 12 minutes. After 
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dehydration with graded series of ethatnol, the sections were mounted with Kaiser’s glycero 
gelatine (Merck, Germany) and coverslips.  
 
4.2.8.2.Immunhistochemistry 
The sections were deparaffinized and rehydrated as mentioned above. Endogenous peroxidase 
was blocked by incubation with 3% hydrogen peroxide (H2O2). Antigen retrieval was 
performed in Antigen Retrieval Solution (Dako, USA) in a microwave at temperatures 
between 90-100°C for 20 minutes. Endogenous avidin and biotin was blocked using the 
Avidin/Biotin Blocking Kit (Vector, USA). The primary antibodies were diluted in 
phosphate-buffered saline (PBS) containing 3% bovine serum albumin (BSA). Additionally, 
the slides were treated for 20 minutes with blocking solution (8% goat serum or rabbit serum 
in PBS with 3% BSA, according to the host species of the secondary antibody) before the 
primary antibody was applied. The following antibodies were used: monoclonal rabbit anti-
Ki67 antibody (ab16667, Abcam, UK), polyclonal rabbit anti-CD31 (ab28364, Abcam,UK), 
polyclonal goat anti-mouse CCL5/RANTES antibody (AF478, R&D systems, USA), 
polyclonal goat anti-human CCR5 antibody (NB100-714, Novus, USA ), polyclonal goat anti-
CCR1 antibody (CKR-1(C-20): sc-6125, Santa Cruz Biotechnology, USA), polyclonal rabbit 
anti-RFP antibody (PM005, MBL Medical & Biological Laboratories, Japan).  
Overnight incubation with the primary antibodies in 4°C fridge was followed by incubation 
with the respective biotinylated secondary antibody (Goat anti-rabbit, BA-1000; Rabbit anti-
goat, BA-5000, Vector, USA), and the ABC reagent for signal amplification at room 
temperature (Vectastain ABC-Peroxidase Kits, PK-4000, Vector, USA ). Between the 
incubation steps the slides were washed in TBS. Further, 3,3’-diaminobenzidine (DAB, Dako, 
USA) was used to develop the color. Finally, the slides were counter-stained with 
hematoxylin and mounted in Kaiser’s glycerol gelatine (Merck, Germany) and coverslips. 
 
4.2.8.3.Ki67 proliferation assay 
After immunohistochemical staining for Ki67 slides were observed at 200× magnification 
using a microscope. Areas showing the highest Ki67 density were chosen and photos were 
taken. These photos were analyzed by Image-Pro Plus 5.0 (Media Cybernetics, Inc., USA). 
For each slide at least three microscopic visual fields (200-fold magnification) were counted. 
The Ki67 index was evaluated in a blinded manner and calculated as Ki67 positive cells 
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divided by all tumor cells in one field90.  
 
4.2.8.4. Microvascular density and vessel thickness analysis 
Staining against the endothelial marker CD31 by means of immunohistochemistry was 
followed by observation at 100× and 200× magnification under the microscope. Tumor slides 
were examined in a blinded manner and representative areas of vital tumor were selected for 
examination. As described by others, spots with the highest density concerning CD31 (“hot 
spots”) were chosen, vessel number per field was counted91, and the thickness of the 
perivascular layer was measured. Each slide was evaluated with 3 fields and the data analyzed 
as mean vessel number or mean vessel thickness of these three fields92, 93 (the measurement of 
vessel thickness is shown in Figure 4.8). 
 
Figure 4.8. Measurement of the mean thickness of perivascular layer by anti-CD31 
staining. a) Schematic figure shows how to measure the thickness of vessels; b) The example 
figure shows the measurement of the vessel thickness under the microscope at 200x 
magnification and valued the distances by pixel. 
 
4.2.9. ELISA analysis of CCL5 secretion of Huh7 and p53-/- MSCs co-culture in vitro 
Murine C57BL/6 p53-/- MSCs were co-cultured with human Huh7 hepatocellular carcinoma 
cells in 6-well culture plates (Nunc, Roskilde, Danmark) in RPMI1640. Cells were co-
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cultured at the following MSC/Huh7 ratios: all MSCs, 4:1, 2:1, 1:1, 1:2, 1:4, all Huh7 at a 
total cell count 1x105 cells. The cell supernatant was collected from the wells after 48 and 72 
hours, respectively. CCL5 levels were detected by ELISA kit according to the manufacturer’s 
instructions (mouse CCL5/RANTES DuoSet ELISA Development kit, R&D Systems, 
Minneapolis, USA). Briefly, a 96-well microplate was coated with capture antibodies (2.0 
μg/ml) overnight at 4°C. Plate contents were emptied and then washed 3 times with 
PBS/Tween-20 solution, and non-specific binding was blocked using 1% BSA in PBS for 1 
hour at room temperature. The blocking buffer was removed and wells were washed for 3 
times. 100 μl samples of the supernatants or standards were added to the coated plate and 
incubated at room temperature for 2 hours. A biotinylated goat anti-mouse CCL5 antibody 
was used as a detection antibody according to the manufacturer’s guidelines. The plate was 
washed 3 times and 100 μl Streptavidin-HRP was added per well. Then the substrate and stop 
solution were added according to instructions. Finally, the plate was read at an optical density 
of 450 nm (GENios Plus, TECAN, Salzburg, Austria). The standard curve was generated 
from a serial dilution of a known-concentration solution of the standard. The concentration of 
the CCL5 was determined by the equation which was created by Excel (Microsoft, USA) 
according to the standard-curve linear regression line. The murine CCL5 concentrations were 
normalized to equal MSC count in each well. 
 
4.2.10. qRT-PCR analysis of Tie2, CCL5 and CCR5 expression in patient liver samples 
Angiogenesis- or stroma-related gene expression, like Tie2, CCL5 or CCR5, was assessed by 
qRT-PCR in human liver specimen obtained from HTCR (Human Tissue and Cell Research, 
Regensburg, Germany). 8 pairs of cancer and normal liver tissue from hepatocellular 
carcinoma patients and 9 other completely normal liver samples were analyzed. Commercial 
real time PCR probes were used for quantitation (see 4.2.10.5). 
 
4.2.10.1. Disruption and homogenization of the tissue  
The tissue samples were taken from the storage -80°C freezer and were brought in liquid 
nitrogen. One of the samples was put on the big dry-ice plate and scratched with a scalpel into 
extremely little pieces. The tissue powder was moved into the 2ml Eppendorf tube with lysis 
buffer (RNeasy Mini Kit, QIAGEN). The tube was vortexed and the content was 
homogenized by 20 gauge syringe for 10 times. Then the tube was centrifuged at full speed 
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for 3 minutes and 400μl supernatant was moved to a new Eppendorf tube.  
4.2.10.2. RNA isolation 
350-400μl of fresh or thawed sample was transferred to a new Eppendorf tube with the same 
volume of 50% ethanol. The following RNA isolation steps were performed according to the 
manufacturer´s instructions using the RNeasy Mini Kit (74106, QIAGEN, Germany). 
 
4.2.10.3. Measurement of RNA concentration 
2μl sample was aspirated from the above step final product, and was mixed with 98μl RNA-
free water. The RNA concentration was determined by RNA/DNA Calculator (GeneQuant 
Pro, GE Healthcare Life Sciences). 
 
4.2.10.4. cDNA synthesis 
2μg of total RNA per 20μl reaction system was conducted, and the cDNA synthesis steps 
were performed according to the manufacturer’s protocol (High-Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems) 
 
4.2.10.5. qRT-PCR TaqMan gene expression assay 
The Platinum Quantitative PCR SuperMix-UDG with ROX (Invitrogen) was used as 
mastermix in this assay. Tie2 (TEK, Hs00945146_m1), CCL5 (Hs00174575_m1) and CCR5 
(Hs99999149_s1) were chosen as TaqMan Gene Expression Assays, and the Eukaryotic 18s 
rRNA (VIC/TAMRA Probe, Primer Limited, 4310893E) was chosen as endogenous control. 
20μl system was applied as real-time PCR probe including 2μl cDNA sample and 18μl system 
mix. The probes were added into 96-well plate, and the plates were analyzed using the ABI 
system 7000 machine (Applied Biosystems, USA). The results were analyzed by Microsoft 
Office Excel 2003. 
 
4.2.11. Statistical analysis 
Statistical significance was assessed by comparing median values using the non-parametric 
Mann-Whitney-U test for independent samples and t-test for random samples (IBM SPSS 
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19.0 for Windows). P values <0.05 were considered significant. Continuous, non-parametric 
data is presented as median [range] values. 
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V. RESULTS 
5.1. MSCs are actively recruited to the site of hepatocellular carcinoma  
5.1.1. MSCs show tropism for recruitment to tumor sites 
In the orthotopic tumor model, human Huh7 hepatocellular carcinoma cells were injected into 
the left lateral lobe of the liver of nude mice. This led to the formation of solid intrahepatic 
tumor xenograft. Using this animal model, the recruitment of systemically injected murine 
MSCs to the tumor site was evaluated. 
5.1.1.1.  SPIO-tranfected MSCs recruit to tumor site 
Superparamagnetic iron oxide nanoparticles (SPIO) have demonstrated their utility as an 
important tool for monitoring transtient labeled MSCs on magnetic resonance (MR) images. 
This work was performed in collaboration with Dr. Mike Notohamiprodjo (Department of 
Clinical Radiology, University Hospitals Munich). The SPIO labelled MSCs (MSCsiron) were 
used to investigate the natural tropism of these cells to tumor site. The mice with 4-week old 
hepatic tumors received intravenous injections of either sterile normal saline, 1×106 unlabeled 
C57BL/6 p53-/- MSCs, or 1×106 SPIO labeled C57BL/6 p53-/- MSCs. After 36 hours of the 
respective injections, mice were sacrificed and evaluated by MR imaging. As control, mice 
without prior tumor cell inoculation also received normal saline or MSCsiron injections and 
were scanned by MRI. Figure 5.1 demonstrates two exemplary cases of tumor bearing mice 
with and without iron-labeled MSCs. The mean size of the orthotopic hepatic tumors was 2cm. 
In non-tumor bearing mice receiving MSCsiron injections, the largest signal decay as compared 
to mice receiving normal saline injections was only detectable in the spleen. This effect was 
not seen in animals receiving unlabeled MSCs. This indicates homing of MSCs after 
intravenous injections to secondary lymphatic organs, such as the spleen which has been 
shown previously30. 
In tumors of animals following injection of SPIO-labeled stem cells, a distinct signal decay in 
T2- and T2*-weight-sequences could be detected. In the R2*-maps, elevation of R2* could be 
detected, indicating an accumulation of iron labelled stem cells, confirmed by histology of 
Prussian blue staining (Figure 5.2 c, d) Tumors of animals receiving either normal saline or 
unlabeled MSC injections did not show a significant signal decay. Injection of unlabeled 
MSCs did not lead to hypo-intense signals inside the spleen of the animals. 
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Figure 5.1. MRI of exemplary cases of tumor bearing mice with SPIO labeled and 
unlabeled MSC. a) Mice were injected with SPIO labeled MSC. The tumor (solid arrows) 
exhibited a hypointense appearance in T2- and T2* (TE=15ms)-weighted sequences. R2*-
calculation reveals an increased spindephasing caused by disturbance of the magnetic field. 
The hyperintense portions of the tumor indicate necrosis. Note that other factors, such as 
bowel air also lead to an increase of R2* (dotted arrow); b) In tumors of mice with unlabeled 
stem cells (empty arrows), non-hemorrhagic tumors exhibited a relatively hyperintense 
appearance and low R2*. Qualitatively, the tumor is much less visible on the R2* maps, 
corresponding to considerably lower R2* values than in a). Both R2* maps are obtained by a 
pixel-based fit to all echo times. 
 
5.1.1.2.Prussian blue staining confirmed the recruitment of SPIO-labeled MSCs 
In order to confirm that the MSCsiron are recruited to the tumor site, the Prussian blue staining 
was conducted. In tumor bearing mice injected with unlabeled MSCs, therewas no iron 
particle in the lung (Figure 5.2 a). Figue 5.2 b demonstrates that only a few iron particles were 
shown in the lung of tumor bearing mice which were injected with MSCsiron. This indicates 
that peripherally injected MSCs reach the pulmonary circulation before they are recruited to 
the tumor site, and after 36 hours, most of them leave the lung for the tumor or other organ 
sites. Moreover, as mentioned above, the Prussian blue positive signals at the liver tumor site 
of MSCsiron injected group proved that the MSCsiron home to the tumor site and cause the 
signal decay in T2- and T2*- weight sequences of MR image (Figure 5.2 c, d). 
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Figure 5.2. Prussian blue staining for detection SPIO labeled MSCs. a) Mice were 
injected with unlabeled MSCs. No iron particle was detected in lung tissue; b,c,d)  Mice were 
injected with SPIO labeled MSCs. A few iron particles were seen in the lung (b, arrow). Many 
iron particles were seen at liver tumor site (c and d, arrowhead). 
 
5.1.2. Reporter gene engineered MSCs promote tumor growth and angiogenesis. 
The tropism of MSCs to the HCC tumor model was confirmed. C57BL/6 p53-/- MSCs were 
engineered with plasmid vectors containing either the Tie2 or CCL5 promoters driving the 
expression of the Red Fluorescent Protein (RFP) reporter gene. These engineered MSCs were 
then injected at a dose of 0.5×106 in the tail vein of HCC bearing mice once per week for a 
period of  three weeks. The general effect of the adoptively transferred MSCs on tumor 
growth as well as the expression of the RFP transgene was monitored. 
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5.1.2.1.Reporter gene engineered MSCs promote tumor growth 
5.1.2.1.1. Total liver weight and volume increased after MSCs injection 
All animals were sacrificed 5 weeks after tumor cell injection and 3 weeks after the first of 
three cycles of injection of MSCs. Total liver weight and volume was evaluated (Figure 4.7). 
At the end of the experiment, there are 10 mice left in the control group, 3 mice in each 
reporter gene engineered MSC group, 5 mice in the Tie2/HSV-TK+ MSC group and 8 mice in 
the CCL5/HSV-TK+ MSC group, as is shown below: 
Group A: no stem cells or GCV injections: 10 mice  
Group B: C57BL/6 Tie2/RFP+ MSCs injections: 3 mice  
Group C: C57BL/6 CCL5/RFP+ MSCs: 3 mice  
Group D: C57BL/6 Tie2/HSV-TK+ MSCs and GCV injections: 5 mice  
Group E: C57BL/6 CCL5/HSV-TK+ MSCs and GCV injections: 8 mice  
The total liver weight, due to increased tumor growth, was increased in mice receiving 
injections of either Tie2- or CCL5- promoter MSCs as compared to mice receiving no stem 
cells. A 1.49-fold elevation between control and Tie2/RFP+ MSCs (median of 5.23 [1.50-
7.20]g vs. median of 7.79 [6.29-9.88]g; *p=0.049), and a 1.58-fold elevation between control 
and CCL5/RFP+ MSCs (median of 5.23 [1.50-7.20]g vs. median of 8.25 [7.33-9.38]g; 
**p=0.007, Table 5.1, Figure 5.3 a) were demonstrated. 
Due to larger tumors total liver volume also was increased in the CCL5/RFP+ MSCs group as 
compared to the control group. A 1.47-fold elevation between control and CCL5/RFP+ MSCs 
(median of 5.30 [1.50-7.50]cm³ vs. median of 7.80 [6.80-9.20]cm³; *p=0.014, Figure 5.3 b) 
were demonstrated. 
Although there was no statistical significant elevation between the control group and the 
Tie2/RFP+ MSCs group (median of 5.30 [1.50-7.50]cm3 vs. median of 8.00 [5.70-9.80]cm³; 
p=0.077), a tendency of increased liver volume could be measured (Table 5.1, Figure 5.3 b). 
Exemplary images of tumors of 3 groups are shown in Figure 5.3 c. 
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Table 5.1. Total liver weight and volume increased after MSCs injection 
 Control Tie2/RFP+ CCL5/RFP+ 
Total liver weight (g) 5.23 [1.50-7.20] 7.79 [6.29-9.88]* 8.25 [7.33-9.38]** 
Total liver volume (cm³) 5.30 [1.50-7.50] 8.00 [5.70-9.80] 7.80 [6.80-9.20]* 
Note: all data is shown as median [range] values. As compared with control group, *p<0.05, 
**p<0.01. 
 
Figure 5.3. Total liver weight and volume increased after MSCs injection. MSC injections 
dosed at 0.5×106 cells per week were intravenously applied starting two weeks after tumor 
cell injection. Total liver weight was evaluated after sacrifice of animals five weeks after 
tumor cell inoculation. Medians were compared and p-values calculated by Mann-Whitney U-
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test for independent samples. a) Box plots of total liver weight show an increase in tumor 
associated liver weight by MSC injections; b) Box plots of total liver volume show an 
increase in tumor volume associated with liver volume by MSC injections (Δ1 is an outlier, 
all * and ** compared with control group, *p<0.05, **p<0.01); c) Macroscopic images of 
three exemplary tumors of each group are shown (left to right: conrtol, Tie2/RFP+ and 
CCL5/RFP+). 
 
The body weight of the animals varied throughout the entire experiment. It showed no 
significant difference in total body weight of animals in the treatment groups (Tie2/HSV-Tk+, 
CCL5/HSV-Tk+) as compared to the control groups (control, Tie2/RFP+, CCL5/RFP+) (Figure 
5.4).  
 
Figure 5.4. Mice total body weight curves. The weight curves show no significant 
difference in total body weight among the control, Tie2/RFP+, Tie2/HSV-Tk+, CCL5/RFP+, 
and CCL5/HSV-Tk+ engineered MSCs groups.  
 
5.1.2.1.2. HE staining of HCC tumors 
Tumor growth was further confirmed by HE staining. In C57BL/6 MSC groups, the dark 
brown/yellow pigmented material or bile pigments, were easily identified in the cytoplasm of 
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tumor cells and in the middle of tubular areas. This reflected extra bile secretion from liver 
cancer cell which may be influenced by the adoptively applied MSCs (Figure 5.5 a). 
Furthermore, hemorrhage and mitosis were detected in these tumors. This may be caused by 
aggressive angiogenesis and consecutive tumor cell proliferation enhanced by MSC 
recruitment (Figure 5.5 b, c). Aggressive tumor groth as reflected by invasion into 
neighbouring organs was also seen in these groups. Figure 5.5 d shows tumor invasion 
directly into proximate bowel. 
 
Figure 5.5. HE staining showed morphologic characteristics changes in C57BL/6 MSCs 
groups. a) Brownish droplets represent the ability of neoplastic hepatocytes to produce bile in 
excess, 200× magnification; b, c) The hemorrhage (arrowheads) and mitosis (star) could be 
detected in tumors indicating the aggressive tumor cell proliferation, 100×, 200× 
magnification; d) Liver cancer cells directly invading into the bowel, 100× magnification. 
 
5.1.2.2.Reporter gene engineered MSCs promote angiogenesis and proliferation 
Microvessel density as measured by immunohistochemical staining against CD31 revealed 
increased angiogenesis in tumors of mice following injection of Tie2/RFP+ MSCs (1.49-fold 
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increase as compared to control group: 9.17 [7.76-12.00] CD31+ vessels / 100× magnification 
field in the control group vs. 13.67 [13.33-17.67] in the Tie2/RFP+ MSC group, *p=0.012). 
Although there is no statistical significant between the CCL5/RFP+ and control group, a 
tendency of increased MVD still can be seen (Table 5.2). Exemplary images of anti-CD31 
staining which are evaluated for MVD of each group are shown in Figure 5.6 first row. 
 
Table 5.2. Effect of reporter gene engineered MSC on tumor angiogenesis and 
proliferation 
 Control Tie2/RFP+ CCL5/RFP+ 
MVD 9.17 [7.76-12.00] 13.67 [13.33-17.67]* 13.00 [10.00-17.33] 
Thickness of vessel 17.72 [7.33-48.33] 42.89 [25.22-141.89] 86.87 [65.22-168.11]*
Ki67 index 0.68 [0.52-0.86] 0.98 [0.89-0.98]* 0.98 [0.98-0.99]* 
Note: all data is shown as median [range] values. MVD, CD31+ vessels / 100× magnification 
field. As compared to control group, *p<0.05. 
 
The vessels in the MSC treated tumors showed broader perivascular staining. As detailed in 
material and methods, the thickness of the perivascular layer was evaluated by CD31 staining. 
Compared to the control group, in the CCL5/RFP+ MSC treated group the thickness of the 
perivascular layer was significantly enlarged (4.89-fold increase compared to control group: 
17.72 [7.33-48.33] pixels in the control group vs. 86.87 [65.22-168.11] in the CCL5/RFP+ 
MSC group, *p=0.012). Although there was no statistical significance between the Tie2/RFP 
and control group, a tendency of an increased thickness of the perivascular layer still can be 
seen (Table 5.2). Exemplary sample images of anti-CD31 staining, which are evaluated as 
perivascular thickness, are shown in Figure 5.6 second row. 
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Figure 5.6. Exemplary microscopic images of anti-CD31 and anti-Ki67 staining of 
tumors in the control, Tie2/RFP+, and CCL5/RFP+ groups 
 
To evaluate the effect of C57BL/6 MSC administration on tumor cell proliferation, Ki67 
indexes were calculated94. Tumors of mice following injections of Tie2/RFP+ and 
CCL5/RFP+ MSCs demonstrated both a 1.44-fold increase in proliferating Ki67+ cells as 
compared to control tumors (0.68 [0.52-0.86] Ki67+ cells / total cells vs. 0.98[0.89-0.98] in 
the Tie2/RFP+ MSC group, and 0.98[0.98-0.99] in the CCL5/RFP+ MSC group, Table 5.2). 
Exemplary images of Ki67+ staining in the control group and following Tie2/RFP+ and 
CCL5/RFP+ MSCs injection are shown in Figure 5.6 last row. 
 
5.1.2.3. MSCs promote cancerous ascites 
No metastases in distant tissues were detected in this study either with or without MSC 
treatment. Wound tumors and bowel invasion were found in both control and MSC groups 
(Table 5.3). All animals in the Tie2/RFP+ MSC treatment group presented with significantly 
more cancerous ascites compared to the non-MSC control group (3/3 in Tie2/RFP+ group vs. 
2/10 in control group, *p<0.05). There was no statistical significance between the CCL5/RFP+ 
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MSC group and the control group regarding ascites formation.  
Table 5.3. Different patterns of cancer cell spread between reporter-gene eMSC and 
control group 
Cancer cell 
spread 
Control 
n=10 
Tie2/RFP 
n=3 
P value 
CCL5/RFP 
n=3 
P value 
Wound 4(40%) 3(100%) 0.161 1(33.3%) 0.937 
Bowel 3(30%) 1(33.3%) 1 1(33.3%) 1 
Ascites 2(20%) 3(100%) 0.049* 2(66.7%) 0.287 
P: eMSC injected groups compare with control group, with Mann-Whitney U test. 
 
5.2.  Stroma- or angiogenesis-related signals and receptor gene expression in MSCs 
recruited to the tumor site 
5.2.1. Systemically injected MSCs can activate Tie2- or CCL5- promoter driven 
reporter genes (RFP) following their recruitment to the HCC microenvironment 
Tumors from the control group and the Tie2/RFP+ or CCL5/RFP+ MSCs treated groups were 
examined for RFP expression by immunohistochemistry. Staining showed strong RFP+ 
signals in tumors that were treated with MSCs expressing RFP either under control of the 
Tie2 promoter / enhancer or the CCL5 promoter.  
Tumor samples were examined for RFP, murine CCL5, and CD31 expresssion by serial 
section immunohistochemistry. CCL5+ signals were only detectable in animals, which had 
received MSCs (Figure 5.7 c, g) as compared to the control group without any CCL5 
expression either in normal liver tissue or in the tumor tissue (Figure 5.7 a, b). In tumors of 
both Tie2/RFP+ and CCL5/RFP+ MSC injected mice, RFP expression (Figure 5.7 e, i) was 
detected in close proximity to CCL5+ (Figure 5.7 c, g) and CD31+ signals (Figure 5.7 d, h) 
indicating that MSCs recruited to the tumor site were integrated into the tumor 
microenvironment in particular tumor stroma and angiogenesis. Following recruitment to the 
tumor microenvironment MSCs expressed the reporter gene RFP by activation of 
angiogenesis- or stroma- related promoters/enhancers such as Tie2 and CCL5.  
 - 53 -
 
 
 - 54 -
 
Figure 5.7. Expression of CCL5, CD31 and RFP in HCC xenografts. a, b) No positive 
signal for CCL5 was seen in either normal tissue or tumor tissue of the control group; c, d, e) 
In the Tie2/RFP+ MSC group, the serial section immunohistochemical stainings demonstrate 
positive signals of CCL5, CD31 and RFP in close proximity; f) Negative control; g, h, i) In 
the CCL5/RFP+ MSC group, the serial section immunohistochemical stainings also 
demosntrate positive signals of CCL5, CD31 and RFP in close proximity; j) Negative control. 
 
5.2.2.  Expression of CCL5 receptors in the tumor stroma  
As shown above, exogenously applied MSCs are actively recruited to HCC tumors and 
express in the context of tumor stroma and tumor angiogenesis the transfected reporter gene 
as well as stroma- or angiogenesis-related markers such as CCL5 and CD31. However, the 
mechanism of how they home to the tumor site has to be further exploited. Both Tie2/RFP+ 
and CCL5/RFP+ MSCs expressed the chemokine CCL5, two of the common receptors of 
CCL5 – CCR5 and CCR1 - were further investigated. Serial section immunohistochemistry of 
tumor tissues was performed using anti-CCR5 and anti-CCR1 antibodies. The 
immunohistochemical results showed that either in the Tie2/RFP MSC group or in the 
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CCL5/RFP MSC group, CCR5 positive signals were in close proximity to CCL5 positive 
signals in the tumor (Figure 5.8).  
 
Figure 5.8. Immunohistochemical staining using anti-CCL5 and anti-CCR5 antibodies 
in Tie2/RFP+ and CCL5/RFP+ MSCs injected tumor tissues. CCR5 positive signals 
(arrows) were in close proximity to CCL5 positive signals (arrowheads) in serial sections of 
both tumor tissues either from the Tie2/RFP+ or the CCL5/RFP+ MSC group. 
 
In serial section immunohistochemical staining of Tie2/RFP MSC injected tumor samples, 
CCR1 positive signals were closed to CCL5 positive signals (Figure 5.9). Based on the serial 
staining results, the ligand and receptor interactions between CCL5 and CCR5 or CCR1 may 
play a key role in the MSCs recruitment.   
 
Figure 5.9. Immunohistochemistry staining of anti-CCL5 and anti-CCR1 antibodies in 
Tie2/RFP MSCs injected mice tumor tissues. CCR1 positive signals (arrows) were close to 
CCL5 positive signals (arrowheads) in the Tie2/RFP MSC groups.  
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5.3.  In vitro data showed that CCL5 is secreted by MSCs 
In order to mimic the interaction between hepatocellular carcinoma cells and mesenchymal 
stem cells, co-culture experiments were conducted followed by ELISA to evaluate the 
chemokine CCL5 expression levels in vitro. According to the in vivo data, the tumor 
microenvironment may attract MSCs through chemokine-receptor interactions like CCL5-
CCR5 or CCL5-CCR1. The stimulating effects of CCL5 expression were supposed to appear 
in vitro in co-cultures using Huh7 cells and C57BL/6 MSCs. However, the ELISA results 
showed that the CCL5 expression level was only related to seeded amount of MSCs (from 
1×105 to 0.67×105) and the incubation time (from 48 hours to 72 hours) (Figure 5.10). There 
was no synergetic effect of stimulating CCL5 expression by co-culturing Huh7 cells with 
MSCs in vitro. 
                          
Figure 5.10. CCL5 expression level of co-culture of Huh7 cells and MSCs in vitro. The 
ELISA results showed that the CCL5 expression level was elevated depending on the seeded 
number of MSCs (from 1×105 to 0.67×105) and the incubation time (from 48 hours to 72 
hours). 
 
5.4.  Tie2, CCL5, CCR5 expression in human samples 
The RNA expression of Tie2, CCL5, and CCR5 in human hepatocellular carcinoma tissue and 
surrounding normal liver tissue was analyzed by qRT-PCR. There was no significant 
difference of expression of all three genes between cancer tissue and concomitant normal 
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tissue (Figure 5.11, pTie2=0.22, pCCL5=0.52, pCCR5 =0.33).  
 
Figure 5.11. RNA expression of Tie2, CCL5 and CCR5 compared between cancer and 
concomitant normal liver tissues. There were no significant differences of expression of all 
three genes between cancer tissue and concomitant normal tissue (all p>0.05). 
Three of the patients examined had liver cirrhosis (Table 5.4). To exclude the influence of 
cirrhosis on carcinogenesis, the Tie2, CCL5 and CCR5 expression levels were re-analyzed 
and compared with total healthy liver tissue (no cirrhosis). 
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Table 5.4. Patients’ clinical data for qRT-PCR result analysis 
no. gender 
main 
diag. other diag.   HBV HCV HIV medication chemo 
35 f HCC     - - - / / 
52 m 
HCC, 
Segment 
V strumectomy, Inguinal hernia HTN - - - Bisoprolol, Duradiuret, Jod / 
63 m HCC Hyperthyroidism   - - - / / 
76 m HCC 
cirrhosis by 
hemochromatosis,oesophageal 
varicose veins I°, COPD   - - - Metformin / 
83 m HCC 
obstructive sleep apnea syndrome, 
strumectomy, vagotomy, akinetic 
parkinson syndrom, peripheral 
arterial occlusive disease(pAVK) 
obesity, 
diabetes 
mellitus, HTN, 
hyperuricemia - - - 
Lasix, ASS, Allopurinol, Thyroxin, 
Madopar / 
103 m HCC sigmoid diverticulum HTN - - - Nifedipin, Antazida, Esomeprozol / 
155 m HCC cirrhosis Child A 
obesity, 
diabetes 
mellitus, HTN - - - Bisoprolol / 
279 m HCC 
cirrhosis Child A, mitral 
insufficiency, hemi-colectomy by 
carcinoma in situ, arterial 
hypertension 
diabetes 
mellitus - - - 
Concor, Norvasc, Diovan, Amaryl, 
Legacon, Thioctacid, Vit B1 / 
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However, there was again no significant difference between cancer and normal tissues in 
CCL5 and CCR5 gene expression (Figure 5.12). Tie2 expression was elevated in normal liver 
tissue compared to tumor tissue (*pTie2=0.01). 
 
Figure 5.12. RNA expression of Tie2, CCL5 and CCR5 compared between cancer and 
total healthy liver tissues. a) Tie2 expression was elevated in normal liver tissue compared to 
tumor tissue (*pTie2=0.01). b) There was no significant difference between cancer and normal 
tissues in CCL5 and CCR5 genes (pCCL5=0.41, pCCR5=0.52). 
 
5.5.  Suicide gene engineered MSCs inhibit tumor growth 
To assess the efficacy of engineered bone marrow derived MSCs as a vehicle for targeted 
gene therapy of hepatocellular carcinoma, the C57BL/6 murine mesenchymal stem cells were 
stably transfected with HSV-Tk suicide gene-based therapeutic constructs. Two suicide gene 
expressing MSC lines were produced: C57BL/6 Tie2/HSV-Tk+ and C57BL/6 CCL5/HSV-Tk+. 
In these cell lines targeted expression of the suicide gene was achieved by setting the HSV-Tk 
gene under the control of the tumor specific promoter/enhancer Tie2 or the promoter CCL5. 
C57BL/6 Tie2/HSV-TK+ and C57BL/6 CCL5/HSV-Tk+ MSCs were injected at a concentration 
of 0.5×106 per week intravenously into mice carrying orthotopically growing HCC xenografts. 
MSC injections were then followed by three days of intraperitoneal ganciclovir (GCV) 
injections at an interval of three days after MSC inoculation (Figure 4.7). 
 
5.5.1. Tumor volume decreased after injection of suicide gene engineered MSCs  
Total liver volume was examined after sacrifice five weeks after tumor cell injection. 
Induction of the suicide gene expression by C57BL/6 Tie2- or CCL5-/HSV-Tk+ MSCs was 
followed by intraperitoneal GCV injections. Treatment with C57BL/6 CCL5/HSV-TK+ MSC 
and GCV led to a statistically significant reduction in the median volume of tumor bearing 
 - 60 -
livers by 66.0% relative to tumor loaded livers of the control group which did not receive 
MSC injections (5.3 [1.5-7.5] cm³ vs. 1.8 [1.0-6.2] cm³; *p=0.027; Table 5.5). Injections of 
C57BL/6 Tie2/HSV-Tk+ MSC and GCV did not lead to a significant difference in total liver 
volume when compared to livers without MSC injections (5.3 [1.5-7.5] cm³ vs. 3.1 [2.9-6.8] 
cm³; p=0.165; Table 5.5).  
Table 5.5. Effect of suicide gene engineered MSCs on tumor growth, angiogenesis and 
proliferation 
 Control Tie2/HSV-Tk+ CCL5/HSV-Tk+ 
Total liver volume (cm³) 5.3 [1.5-7.5] 3.1 [2.9-6.8] 1.8 [1.0-6.2]* 
MVD 9.17 [7.67-12.00] 10.33 [4.00-16.33] 11.33 [6.33-16.00] 
Ki67 index 0.68 [0.52-0.86] 0.57 [0.40-0.90] 0.67 [0.38-0.73] 
Note: all data is shown as median [range] values. MVD, CD31+ vessels / 100× magnification 
field. As compared with control group, *p<0.05. 
 
When comparing total liver volume after CCL5/HSV-Tk+ MSC treatment to tumor bearing 
livers after CCL5/RFP+ MSC injections, the reduction of total liver volume was 76.9% (7.8 
[6.8-9.2] cm³ vs. 1.8 [1.0-6.2] cm³; *p=0.012; Table 5.6, Figure 5.13 a). However, Tie2/HSV-
Tk+ MSC treatment showed no significant reduction of total liver volume as compared to 
Tie2/RFP+ MSC injections (8.0 [5.7-9.8] cm³ vs. 3.1 [2.9-6.8] cm³; p=0.071; Table 5.6, 
Figure 5.13 b) 
Table 5.6. Total liver volume and Ki67 index in all 5 groups 
 Control Tie2/RFP+ Tie2/HSV-Tk+ CCL5/RFP+ CCL5/HSV-
Tk+ 
Total liver 
volume (cm³) 
5.3 
[1.5-7.5] 
8.00 
[5.70-9.80] 
3.1 
[2.9-6.8] 
7.80 
[6.80-9.20] 
1.8 
[1.0-6.2]* 
Ki67 index 0.68 
[0.52-0.86] 
0.98 
[0.89-0.98] 
0.57 
[0.40-0.90] 
0.98 
[0.98-0.99] 
0.67 
[0.38-0.73]* 
Note: all data is shown as median [range] values. *p<0.05, both demonstrate CCL5/HSV-Tk+ 
group compared with CCL5/RFP+ group. 
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Figure 5.13. CCL5/HSV-Tk+ and Tie2/HSV-Tk+ MSCs inhibited tumor growth.                  
a) Compared to the CCL5/RFP+ group the total liver volume significantly decreased in the 
CCL5/HSV-Tk+ group (*p<0.05); b) Compared to the Tie2/RFP+ group the Tie2/HSV-Tk+ 
group showed a tendency of decreased total liver volume without statistical significance 
(p>0.05), °8 was missing value. There was also no statistically significant difference in total 
liver volume comparing treatment with Tie2/HSV-TK+ vs. CCL5/HSV-Tk+ transfected MSCs 
(Table 5.6, p=0.127) 
 
5.5.2. Effect on microvessel density 
Microvessel density did not differ significantly between the groups of HSV-TK+ MSC 
treatment and the control groups without MSC administration (9.17 [7.67-12.00] CD31+ 
vessels / 100× magnification field in the control group vs. 10.33 [4.00-16.33] in the Tie2/HSV-
TK+ group (p=0.833) and 11.33 [6.33-16.00] in the CCL5/HSV-TK+ group (p=0.328), 
Tie2/HSV-TK+ group vs. CCL5/HSV-TK+ group (p=0.943); Table 5.5). 
 
5.5.3. Effect on tumor proliferation 
The median percentage of Ki67+ proliferating cells within tumors of HSV-Tk+ MSC injected 
animals did not significantly differ from that of the control group (0.68 [0.52-0.86] Ki67+ 
cells/total cells in the control group vs. 0.57 [0.40-0.90] in the Tie2/HSV-Tk+ group (p=0.931) 
and 0.67 [0.38-0.73] in the CCL5/HSV-Tk+ group (p=0.329); Table 5.5). However, 
CCL5/HSV-Tk+ MSC treatment led to a significantly reduced Ki67 indexes as compared to 
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CCL5/RFP+ MSC administration (0.98 [0.98-0.99] in the CCL5/RFP+ MSC group vs. 0.67 
[0.38-0.73] in the CCL5/HSV-Tk+ group (*p=0.036); Table 5.6, Figure 5.14 a, b). No 
statistical significance regarding Ki67 index was found between Tie2/RFP+ and Tie2/HSV-Tk+ 
groups (0.98 [0.89-0.98] in Tie2/RFP+ group vs. 0.57 [0.40-0.90] in the Tie2/HSV-Tk+ group 
(p=0.071); Table 5.6, Figure 5.14 c, d). 
 
Figure 5.14. Comparison of Ki67 after injection of different promoter engineered MSCs. 
a) CCL5/HSV-Tk+ MSC treatment led to significantly reduced Ki67 indexes as compared to 
CCL5/RFP+ MSC administration (*p=0.036); b) Exemplary anti-Ki67 staining of each CCL5 
promoter group is shown; c) No statistical significance has been found between Tie2/RFP+ 
and Tie2/HSV-Tk+ groups (p=0.071), the tendency in a decrease of Ki67 coud be 
demonstrated; d)  Exemplary anti-Ki67 staining of each Tie2 promoter group is shown. 
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VI. DISCUSSION 
6.1. Therapy of HCC  
Hepatocellular carcinoma is a major health problem with increasing incidence. With the 
continuted development of surgical technologies, radical resection of tumor lesions and liver 
transplantation have become the standard curative therapies for this cancer. However, a 
majority of patients can not undergo resection because of advanced tumor stage. For these 
patients limitations in the availability of liver donors lead to therapy delay and consequently 
tumor progression. To improve prognosis, and potentially reduce the tumor stage, PEI, RFA, 
and TACE, are applied as bridging therapies. A series of prospective and retrospective studies 
have shown that there is no significant difference, or better outcome, on tumor progression 
when comparing these bridging therapies with radical resection95-98. Regardless of the 
mechanism applied by these individual various bridging therapies to suppress tumor growth, 
whether with physical effects such as cryoablation or radiofrequency ablation, chemical 
effects such as alcohol injection, or by combining the physical and chemical effects used in 
chemoembolization, significant damage to normal tissues occur in concert with the 
“suppression” of tumor growth. To better protect normal tissue and at the same time to 
selectively kill cancer cells and cancer associated stromal cells we evaluated the use of 
genetically engineered MSCs for selectively targeting of tumor stroma and angiogenesis as 
therapy of HCCs. As seen with other tumor entities, HCC is capable of building a tumor 
stroma comprised of cellular components that help to support tumor progression39, 99, 100. HCC 
tumor stroma also includes an extensive tumor vasculature suggesting strong activation of 
proangiogenic signaling pathways101. These characteristics of HCC represent potential targets 
for therapeutic intervention. The potential targeting of this biological phenotype to inhibit 
HCC tumor growth is the central aim of this thesis.  
MSCs are seen as potential candidates for cell-based cancer therapy based on several 
properties of the cells: 1) they have a natural tropism for recruitment to solid tumor sites; 2) 
they are reasonably simple to isolate; 3) they can be greatly expanded in vitro; 4) they retain 
the potential to differentiate under exogenous stimuli; 5) they lack immunogenicity; 6) they 
can be easily transduced by genetic vectors in vitro; and 7) they can be delivered systemically 
or locally102.  
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6.2.SPIO-labeled MSCs home to the tumor site from the peripheral circulation 
Transient transfection of MSCs with iron particles (SPIO) allowed us to quantify the 
recruitment of MSCs into the tumor of HCC bearing mice using MRI as imaging technology. 
SPIO-labeled MSCs appeared as hypointense (dark) in the MRI due to significant shortening 
of the T2 and T2* relaxation times because of the incorporation of iron oxide nanoparticles in 
endosomes. We hypothesized that the recruitment of these MSCsiron could be observed under 
MRI scaning. The MSCsiron were injected into the tail vein. Three days later, after their 
recruitment to the tumor site, scaning of the T2 and T2* relaxation time by MRI was 
performed and showed a clear signal decay in the liver of MSCiron injected mice. The 
recruitment of MSCsiron was subsequently confirmed in paraffin-embedded sections using 
Prussian Blue staining. This approach will be developed in future studies for the direct 
quatification of MSC distribution in tumors and non-tumor tissues. Importantly, the 
magnetically labeling of stem cells does not appear to alter cell metabolism, function, 
proliferation, viability, or differentiation capacity, and has not been associated with short- or 
long-term toxicity issues103-105. Interestingly, only a few iron-positive cells were seen in the 
lung three days after injection. MSCs have been previously shown to be arrested in the lung 
early after peripheral application. This is thought to result from the large irregular size of the 
MSCs that result from their culture in vitro. The results here suggest that MSCs injected 
through tail vein enter the peripheral circulation and stay transiently within the pulmonary 
microcirculation. The cells eventually leave the lung and are distributed by the peripheral 
circulation, and finally, are selectively attracted by the chemokine / cytokine signals that 
derive from the tumor environment. They can be found in the tumor site by day 3-4 after 
injection.  As discussed the use of MSCsiron is being developed for the quantification and 
distribution of adoptively transferred MSCs. For future investigations, the T2 sequence signal 
of the MRI will be recorded before MSCiron injection. This should allow a measurement in the 
context of titration of cell numbers relative to MRI signals allowing the generation of a 
standard curve. Following injection of the cells the regional liver signals can be quantified. 
Thus, the comparable signal decay can be used to evaluate the percentage of cells which 
arrive at the destination. In summary, labeling of MSCs with SPIO and the use of MR 
imaging provides a non-invasive method for tracking and quantifying the fate of transplanted 
cells in vivo.  
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6.3.Adoptively transferred MSCs promote tumor growth, angiogenesis, proliferation, 
and ascites formation 
In comparison to untreated controls, the control MSC were found to significantly promote 
tumor growth (Table 5.1, Figure 5.3). Qiao and Kidd reported that MSCs could inhibit 
hepatocellular carcinoma and pancreatic cancer growth28, 38. In these studies, the MSCs were 
co-injected with tumor cells in vivo. The apparent conflicting results may be explained by the 
different experimental approach: in our animal model MSCs were injected in already well 
established tumor systems. Our group has also confirmed these general results in other cancer 
models, including pancreatic cancer30, 31. In these settings control MSCs were found to 
strongly promote tumor growth. It has been proposed that endogenous MSCs are actively 
recruited to tumors under physiologic conditions, where they assist with tissue repair, and in 
so doing, provide a microenvironment supporting tumor growth.  
Both tumor weight and volume alterations were evaluated on the basis of total liver weight 
and volume. The orthotopic hepatocellular carcinoma model was established by intra-
parenchymal injection of the human HCC cell line Huh7. The model generally induces one 
tumor lesion at the puncture site, but also leads to intra-hepatic metastatic lesions. There is 
generally a lack of metastases in distant tissues with or without MSC injection. Weight curves 
of the mice showed no significant difference in total body weight among the control and MSC 
treated groups (Figure 5.4). Total liver weight or volume was increased in mice receiving 
injections of reporter gene engineered MSCs as compared to mice receiving no MSCs at all 
due to larger tumors. 
Macroscopically, the exogenously added MSCs strongly promoted tumor growth. 
Microscopically, MSCs also exacerbated bile secretion, invasion, and mitosis of the tumors. 
Engineered MSCs were found to induce numerous hemorrhages within the tumor area.  
CD31 is an epithelial vascular cell surface marker.  IHC performed using an anti-CD31 
antibody was conducted to evaluate the effect of MSCs on tumor angiogenesis. Both micro-
vascular density (MVD) and thickness of vessels were elevated in the MSC injected groups as 
compared to the control group. Angiogenesis is a key step in tumor progression: on the one 
hand, MSCs were found to promote angiogenesis in liver cancer; on the other hand, effective 
targeting of this process could limit tumor growth. MSCs are thought to differentiate into 
endothelial cells or pericytes, and thus participate in tumor angiogenesis4, 106. MVD 
demonstrated an increased vessel number in MSC treated tumors. An increased thickness of 
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these vessels is demonstrated by a broader perivascular staining in these groups. 
IHC with Ki67 antibody was used to investigate cancer cell proliferation. The Ki67 index 
reflects the general proliferation rate of tumor. Here we confirmed that MSCs promote tumor 
proliferation compared to the control group (Table 5.2, Figure 5.6).  
 
6.4.Expression of reporter genes in the context of tumor stroma and angiogenesis 
Cell fate is largely determined by the orchestration of specific gene expression programs. The 
capacity of a progenitor cell to differentiate into other cellular lineages is controlled by the 
activity of transcription factors that are capable of reprogramming gene networks. In 
eukaryotic cells promoters in concert with enhancers drive tissue specific expression through 
their interaction with specific transcription factors and mediators. MSCs have multilinage 
differentiation capacity. After recriutment to tumor stroma they start to undergo 
differentiation into stroma related cells and initiate the secretion of stroma related signals (e.g. 
CCL5)42, 107. In the context of the studies outlined here the CCL5 promoter can drive 
expression of genes when MSCs interact with the tumor microenvironment. When used to 
drive expression of reporter genes (e.g., RFP, GFP, Gluc) or the suicide genes (e.g., HSV-Tk, 
iCasp9) the CCL5 promoter effectively induce their expression within the tumor stroma. A 
similar approach was used to drive expression of transgenes in the context of tumor hypoxia 
and angiogenesis. Here the MSCs differentiate into endothelial related cells and induce 
expression of angiogenesis related signals including Tie2. Consequently, the Tie2 promoter / 
enhancer was employed to drive the expression of transgenes in the context of tumor 
angiogenesis. 
The homing and activation of MSCs within a tumor environment were verified using 
engineered MSCs to express the reporter gene RFP under the control of either the Tie2 
promoter / enhancer or the CCL5 promoter. Tie2 is a cell surface receptor that binds to and is 
activated by the angiopoietins (Ang1, Ang2, Ang3, and Ang4). Studies have shown that 
MSCs can act as precursors for carcinoma associated fibroblasts, endothelial cells, or 
pericytes108, 109. CCL5 (Chemokine (C-C motif) ligand 5), also known as RANTES 
(Regulated upon Activation, Normal T-cell Expressed, and Secreted), is a chemokine which is 
induced in tumor stroma and is chemotactic for T cells, eosinophils, basophils, and other cells. 
Following their integration into tumor stroma, MSCs exert effects at least partly through their 
secretion of factors including CCL542. In our studies RFP expression was placed under the 
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control of a Tie2 or CCL5 promoter, supporting conditional activation of the transgene in the 
context of either angiogenesis or tumor stroma. Serial section staining with anti-RFP indicated 
that RFP signals were found proximal to the CCL5 and CD31 signals, strongly suggesting 
MSC association to tumor stroma or angiogenesis. 
 
6.5.Chemokines and their receptors play a predominant role in MSCs’ recruitment  
The mechanism underlying the recruitment of MSCs to the tumor site remains an open 
question.  A number of groups have demonstrated that growth factors and chemokines are 
released from cancer cells. These factors can promote the migration of MSCs from bone 
marrow towards the tumor site. Such as vascular endothelial cell growth factors (VEGFs), 
transforming growth factors (TGFs), fibroblast growth factors (FGFs), epidermal growth 
factors (EGFs), stromal cell-derived growth factor-1 α (SDF-1 α)/CXCL12, platelet derived 
growth factors (PDGFs), IL-1β, IL-8/CXCL8, monocyte chemoattractant protein-1 (CCL2), 
and CCL5, which are released from the tumor environment are possible candidates in the 
mobilization and chemotaxis of progenitor cells towards target tissues17, 42, 110-115. Additionally, 
inhibition of the tumor associated inflammatory response by an anti-inflammatory agent, 
which down-regulates NF-κB, VEGF, IL-6, CCL3, and CCL25, resulted in the inhibition of 
MSC recruitment38. Most recently, Quante and associates illustrated that the recruitment of 
MSCs to the tumor was dependent on TGF-β- and SDF-1α116. CCR1 and CCR5 are two 
common receptors for CCL5. The IHC results here showed that CCR1 and CCR5 positive 
signals were located proximal to the CCL5 signals (Figure 5.8, 5.9) supporting the potential 
role of these ligand receptor interactions in the targeting of MSCs to tumor stroma. 
 
6.6.Stroma and angiogenesis gene expression in human HCC and normal samples 
Quantitative RT-PCR assays were used to study the differential expression of Tie2, CCL5, 
and CCR5 genes in human HCC samples and adjacent normal liver tissues. However, there 
was no significant difference found in the mRNA levels of the three genes between tumor 
tissue and and adjacent normal liver samples (Figure 5.11). Based on the clinical data of the 
patients, most of them suffered from liver cirrhosis (Table 5.4). The apparent bias in gene 
expression may be caused by the background of a chronic disease in these samples. To help 
addressing this qRT-PCR was conducted in patient liver tumor samples and compared to 
healthy liver samples. Here again we observed no difference in CCL5 or CCR5 expression 
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relative to endogenous controls (Figure 5.12 b, c). However, there was a significant increase 
in the expression of Tie2 in the healthy tissue group (*p=0.01, Figure 5.12 a) as compared to 
the tumor group. HCC is generally regarded as a hypervascular tumor, the angiogenesis 
related gene Tie2 should be highly expressed in tumor tissue. However, as Zhao and Zhang 
reported117, 118, there was no significantly different expression of Tie2  between HCC and non-
cancerous liver tissue. The differetial expression of Tie2, CCL5, and CCR5 in tumor and 
normal tissues suggests that it is important to intergrate the general expression of 
inflammatory cytokines and the level of tumor differentiation when planning future 
experiments119, 120. 
  
6.7.Suicide gene engineered MSCs followed by GCV application inhibit tumor growth  
For therapeutic application MSCs were engineered to express the herpes simplex virus – 
thymidine kinase (HSV-Tk) under the control of the Tie2 promoter / enhancer or the CCL5 
promoter. The cells were injected into the peripheral circulation and three days later, the 
animals were treated with the prodrug ganciclovir (GCV). The mechanism of HSV-Tk suicide 
gene killing has been well characterized. The HSV-Tk gene is derived from the Herpes 
simplex virus. It is an enzyme that phosphorylates the prodrug ganciclovir to the active form 
GCV-triphosphate (GCV-TP), which subsequently inhibits cellular DNA polymerases and 
acts as a chain terminator in DNA synthesis, thereby selectively killing dividing cells107. The 
major mechanism responsible for GCV-TP transfer into neighboring cells is their transfer 
through gap junctions that are established between neighbouring cells. In this way, the tumor 
cells which are not transduced with the suicide gene, also become sensitive to prodrugs and 
are eliminated along with the suicide gene-transfected MSCs referred to as the “bystander 
effect”. One advantage of using HSV-Tk as a suicide gene in MSC is that it demonstrates not 
only bystander cytotoxic effect on tumor cells, but eliminates even those MSCs that have not 
been activated within the tumor environment121 since a small level of promoter activity is still 
seen in MSCs at other locations leading to cells that become sensitive to GCV treatment. This 
effectively limits potential MSC driven side effects. In addition to its use as a therapeutic gene, 
HSV-Tk has also been developed as a marker for non-invasive imaging. HSV-Tk-specific 
tracers, like [18F]FHBG and [124I]FIAU can be detected by PET imaging in HSV-Tk 
expressing MSCs25. However, the HSV-Tk and GCV setting does have drawbacks. For 
example, GCV only kills proliferating cells and does not kill postmitotic cells122. Some other 
suicide genes are currently under investigation including iCasp9123.  
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It remains an open question when it is most suitable to inject GCV after application of MSCs. 
Here we chose a three-day interval between MSC injection and GCV treatment. First, after 
MSC injection in the tail vein, they had to traffic through the body and potentially to leave the 
lung before eventually reaching the tumor site. Second, the MSCs need time to undergo 
differentiation and activation of the transgenes. The bystander effect that underlies the use of 
Tk-GCV here requires time to be “communicated” to the surrounding cells. Amano et al 
showed that HSV-Tk transfected MSCs required at least three days before GCV induced cell 
death occurred in vitro26. For these reasons, the MSCs were given three days to home to the 
tumor environment, proliferate, and set up tight junctions with bystander tumor cells.  
 
 - 70 -
VII. PERSPECTIVES 
From a clinical perspective, MSC based gene therapy appears to be more feasible for clinical 
application than many other cell therapy approaches currently under study. This is based on 
the observation that MSCs are easy to obtain from adult subjects, for example, they can be 
isolated from patient´s bone marrow, adipose tissue, umbilical cord blood, placental tissue, 
amniotic fluid, peripheral circulation, and even tumor tissue124-129. After isolation, they can be 
expanded in vitro and are relatively easy to transfect with transgenes. In a future clinical trial, 
each patient could be treated with autologous MSCs. This obviates potential immunologic 
incompatibilities. Intravenous injection of MSCs has the advantage that repeated injections 
over an extended period are clinically feasible.  
Practically, this approach could likely be partnered with existing strategies. For example, in 
hepatocellular carcinoma, TACE is generally applied as a bridging therapy to to control tumor 
growth. If performed in concert with MSC injection, an enhanced therapeutic effect may be 
seen. However, recent studies have shown that adoptively applied MSCs can protect tumor 
cells from chemotoxicity130. The effect was transient and suggests that while the two therapies 
can not be co-applied, a therapeutic schedule that limits potential negative effects of MSCs 
has to be developed. The application of engineered MSCs represents an important new 
approach for the treatment of solid tumors.  
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VIII. SUMMARY 
 MSCs home to the tumor site from the peripheral circulation, and when transfected with 
SPIO, their recruitment to the tumor site can be followed and evaluate by MRI scaning 
 Engineering MSCs express the reporter gene RFP by activation of the tissue-specific 
promoters CCL5 or Tie2 in the context of tumor stroma and angiogenesis 
 MSCs promote tumor growth, angiogenesis, and proliferation as they differentiate into 
tumor stromal cells and angiogenic endothelial cells 
 MSCs may potentially be recruited to the tumor site through ligand-receptor interaction 
between CCL5, CCR5, and CCR1 
 There is no differential expression of Tie2, CCL5, and CCR5 between normal and tumor 
tissues of HCC patients and healthy normal hepatic tissue 
 Suicide gene engineered MSCs under the control of tissue-specific promoters targeting 
tumor stroma or angiogenesis followed with GCV injection can inhibit experimental HCC 
tumor growth in mice 
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IX. ZUSAMMENFASSUNG 
Einleitung 
Mesenchymale Stammzellen (MSCs) spielen eine entscheidende Rolle in der Tumorbiologie. 
Unter anderem werden MSCs nach Rekrutierung in einen wachsenden Tumor in das 
Tumorgefäßsystem eingebaut. In präklinischen Untersuchungen konnte beispielsweise für das 
Mammakarzinom gezeigt werden, daß in Richtung Tumorstroma rekrutierte MSCs selbst 
durch Sekretion des Cytokins RANTES (CCL5) Tumorwachstum und Metastasierung 
unterstützen. In eigenen Vorarbeiten konnte nachgewiesen werden, daß exogen zugeführte 
MSCs substantiell in Tumoren wie Pankreaskarzinomen homen. Daher sind MSCs potentielle 
Transportvehikel für therapeutisch wirksame Gene im Kontext eines wachsenden Tumors, 
insofern sie für hoch selektive, gewebsspezifische Expression entwickelt werden. In 
Vorarbeiten haben wir immortalisierte MSCs (imMSCs) stabil mit dem Herpes simplex virus 
(HSV) - Thymidinkinase (tk) Gen unter der Kontrolle des Tie2 Promoter/Enhancer transfiziert, 
der hoch selektiv im Rahmen der Angioneogenese beim Pankreaskarzinom zur Genexpression 
führt. Die Tk-Expression führt zur Phosphorylierung des Prodrugs Ganciclovir (GCV), 
welches dann zum Zelltod der transfizierten Zelle und angrenzender Zellen (andere Endothel- 
oder Tumorzellen) über den sog. Bystandereffekt führt.  
Ziel war es nun, den biologischen Mechanismus der stammzell-basierten, primär gegen die 
Angioneogenese gerichteten Therapie auf eine das Tumorstroma adressierende Therapie 
auszudehnen und beim humanen hepatozellulären Karzinom zu evaluieren. Dazu wurden 
MSCs mit der Herpes Simplex (HSV) Thymidinkinase (Tk) unter der Kontrolle des CCL5- / 
Tie2-Promoters zur gewebsspezifischen Genexpression stabil transfiziert. Zur Lokalisation 
der MSCs in Assoziation zum Therapieeffekt werden diagnostische Tie2/CCL5-RFP 
enthaltende MSCs eingesetzt. 
Methodik 
MSCs wurden aus dem Knochenmark von C57BL/6 p53 knock-out Mäusen isoliert, 
charakterisiert und kultiviert. Diese wurden mittels Elektroporation jeweils mit HSV-Tk oder 
Red Fluorescent Protein (RFP) unter der Kontrolle des CCL5- und Tie2-Promoters stabil 
transfiziert. Für die in vivo Versuche wurde ein orthotopes Mausmodell verwendet, wobei 
humane Huh7 HCC-Tumorzellen in die Leber von immuninkompetenten Nacktmäusen 
(Balb/c nu/nu) injiziert wurden. Die RFP und HSV-Tk transfizierten Stammzellen sowie die 
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nativen MSCs wurden über 3 Wochen einmal wöchentlich intravenös über die Schwanzvene 
injiziert. Die HSV-Tk Therapiegruppe erhielt in jedem Zyklus an den Tagen 5-7 nach 
Stammzellgabe Ganciclovir durch intraperitoneale Verabreichung. Nach 36 Tagen wurden die 
Tiere getötet und neben Erfassung des makroskopisch sichtbaren Tumorbefalls,  histologische 
und immunhistochemische Untersuchungen verschiedener Gewebe vorgenommen.  
Ergebnisse 
In der Mikroskopie konnten RFP-Signale in den Tumorgewebeproben der entsprechenden 
Stammzellgruppen, nicht jedoch in der Kontrollgruppe, detektiert werden. Im orthotopen 
HCC-Model konnte gezeigt werden, dass die CCL5/HSV-Tk transfizierten Stammzellen in 
Verbindung mit Ganciclovir zu einer signifikanten Tumormassenreduktion um 66% 
gegenüber der unbehandelten Gruppe führten (p<0.05). Der Effekt auf das Tumorwachstum 
war deutlicher nach Gabe von CCL5/HSV-Tk MSCs im Vergleich zu Tie2/HSV-Tk MSCs. 
Ferner konnte gezeigt werden, dass die systemische Gabe von nativen MSCs oder 
diagnostischen RFP-MSCs das Tumorwachstum fördert. 
Schlussfolgerung 
Die erhobenen Daten weisen darauf hin, dass MSCs und die Aktivierung des CCL5- / Tie2-
Promoters für das Wachstum und das Metastasierungspotential des hepatozellulären 
Karzinoms eine Rolle spielen. Die RFP Genexpression im Tumorgewebe nach Gabe von 
diagnostischen Tie2/CCL5-RFP enthaltende MSCs zeigt aktives Homing der exogen 
zugeführten MSCs ins Tumorgewebe. Des Weiteren zeigte sich eine Reduktion des 
Primärtumorgewichts und der Metastasierungsrate nach Gabe von therapeutischen HSV-Tk-
MSCs unter Ganciclovir, wohingegen sich native MSCs oder RFP-MSCs am 
Tumorwachstum beteiligen. Eine auf das Tumorstroma oder Angiogenese zielende MSCs 
basierte CCL5-/Tie2-HSV-Tk-Suizidgentherapie stellt damit eine erfolgversprechende 
Therapiestrategie beim hepatozellulären Karzinom dar, wobei weitere experimentelle 
Untersuchungen zur Optimierung dieser Behandlungsstrategie und zur nicht-invasiven 
Erfassung des Therapieerfolgs (in vivo imaging) bis zur Entwicklung einer klinischen Studie 
erforderlich sind. 
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X. ABBREVIATION 
 
5-FC, 5-fluorocytosine 
5-FU, fluorouracil  
C57BL/6, C57 black 6 mouse 
CCL5, chemokine (C-C motif) ligand 5 
RANTES, regulated upon activation normal T cell expressed presumed secreted  
CCR1, 5, C-C chemokine receptor type 1,5 
CD, cytosine deaminase 
CD, cluster of differentiation, CD14, CD19, CD34, CD45, CD73, CD 90, CD105 
CMV, cytomegalovirus 
CX3CL1, RGDFKN  
DMEM, Dulbecco's modified eagle medium 
DMSO, dimethyl sulfoxide 
ELISA, enzyme-linked immunosorbent assay 
Fe, ferrum 
GCV, ganciclovir 
GFP, green fluorescent protein 
HCC, hepatocellular carcinoma  
HE, hematoxylin and eosin 
HLA-DR, human leukocyte antigens-DR (major histocompatibility complex, MHC class II) 
HSV-Tk, herpes simplex virus-thymidine kinase 
hTERT, human telomerase reverse transcriptase 
IFN-β, beta-Interferon 
IL, interleukin, IL-1β, IL-2, IL-8, IL-12, IL-17, IL-22 
iNOS, inducible nitric oxide synthase  
i.v., intravenous 
MHC-I, major histocompatibility complex class I 
MRI, magnetic resonance imaging 
MSC, mesenchymal stem cell  
      eMSC, engineering mesenchymal stem cell 
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hBM-MSC, human bone marrow-derived mesenchymal stem cell 
hAT-MSC, human adipose tissue-derived mesenchymal stem cell 
mMSC, mouse bone marrow-derived mesenchymal stem cell 
rMSC, rat bone marrow-derived mesenchymal stem cell 
MVD, microvascular density 
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells 
NK4, antagonist of hepatocyte growth factor (HGF) 
PDL, population doubling level  
PEDF, pigment epithelium-derived factor  
PEI, percutaneous ethanol injection 
RFA, radio frequency ablation 
RFP, red fluorescent protein 
ROR-γ, RAR-related orphan receptor-gamma 
s.c., subcutaneous  
SPIO, supermagnetic iron oxide 
TACE, transcatheter arterial chemoembolization 
T-cell, T lymphocytes 
Tie2, angiopoietin receptor 2 
TGFβ, transforming growth factor beta 
TNF-α, tumor necrosis factor-alpha 
TRAIL, tumor necrosis factor-related apoptosis-inducing ligand 
VEGFR-1, vascular endothelial growth factor receptor-1 
VPCs, vector-producing cells 
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